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ACRONYMS 
 
 
PDAC: Pancreatic Ductal Adenocarcinoma 
 
PKC: Protein Kinase C  
 
Lats: Large tumor suppressor kinase 
 
P-S127: phosphorylated Serine 127 
 
TEAD: TEA Domain Family Member  
 
CTGF: Connective Tissue Growth Factor 
 
PK: Pharmacokinetic 
 
BA: Bioavailability 
 
PanIN: Pancreatic Intraepithelial Neoplasia 
KRAS: Kirsten Rat Sarcoma viral oncogene homolog 
p16INK4A/CDKN2A: Cyclin-Dependent Kinase Inhibitor 2A 
TP53: Tumor Protein p53 
SMAD4/DPC4: Mothers Against Decapentaplegic homolog 4 
BRCA2: Breast Cancer type 2 
CDK: Cyclin-Dependent Kinase 
Rb-1: Retinoblastoma 1 
TGF-β: Transforming Growth Factor-β 
SH3 BM: Src homology domain 3 binding motif  
RUNX: Runt-related transcription factor 
MST1: Macrophage Stimulating 1 
AJs: Adherens Junctions 
TJs: Tight Junctions 
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AMOT: Angiomotin 
AMOTL: Angiomotin Like 
LPA: Lysophosphatidic Acid  
S1P: Sphingosine 1-Phosphate  
GPCR: G-Protein-Coupled Receptor  
PTMs: Post-Translational Modifications 
SN: Nucleophilic Substitution 
CBP: CREB-Binding Protein 
 
K: Lysine  
 
S: Serine 
 
Sirt: Sirtuin 
 
PML: Promyelocytic Leukemia 
 
MBP: Bone Morphogenetic Protein 
 
AREG: Amphiregulin 
 
FGF: Fibroblast Growth Factor 
 
EMT: Epithelial-to-Mesenchymal Transition  
 
ECM: Extracellular Matrix 
 
PSCs: Pancreatic Stellate Cells 
 
MEK/ERK: MAP kinse-ERK kinase 
 
GSK: Glycogen Synthase Kinase  
 
PPARγ: Peroxisome-Proliferator-Activated Receptor γ 
  
CEBPα: CAATT Enhancer-Binding Protein α  
 
MDR: Multidrug Resistance 
 
MDRP1: Multidrug-Resistance like Protein 1 
 
ChIP: Chromatin Immoprecipitation 
 
DMSO: Dimethyl Sulfoxide  
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DMEM: Dulbecco's modification of Eagle's medium 
 
FCS: Fetal Calf Serum 
 
EGF: Epidermal Growth Factor 
 
PFA: Paraformaldehyde  
 
PBS: Phosphate Buffered Saline  
 
DAPI: 4',6-diamidino-2-phenylindole  
 
SDS-PAGE: Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis 
PVDF: Polyvinylidene Difluoride 
IEF: Isoelectric Focusing 
DTE: 1,4-Dithioerythritol 
 
IAA: Iodoacetamide 
 
BBP: Bromophenol Blue 
 
GAPDH: Glyceraldehyde-3-phosphate Dehydrogenase 
 
IC50: Half maximal inhibitory concentration 
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ABSTRACT 
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Research activity within the frame of the FP7 European project 
PANACREAS:Integrating chemical approaches to treat pancreatic cancer: 
making new leads for a cure. 
 
Identification of new potential drug candidates targeting the 
Yes Associated Protein, YAP, in pancreatic ductal 
adenocarcinoma  
 
The yes-associated protein, YAP, is a transcriptional co-activator, able to 
regulate the expression level of a wide range of target genes. Despite 
deregulation of YAP has been associated with cancer etiology, no compounds 
are known to specifically modulate its functions. Here we identified an inhibitor 
of YAP functionality, called GF 10923X, and we proposed it as a potential lead 
molecule to be used against disease where YAP is found deregulated, 
pancreatic ductal adenocarcinoma (PDAC) included. GF 109203X is an already 
known kinase inhibitor, preferentially targeting PKCα. We developed a high 
throughput approach by which we identified this compound able to reduce YAP-
induced proliferation and clonogenicity of PDAC cellsin vitro, despite it leads to 
increased YAP nuclear levels. The Hippo pathway is the main inhibitor of YAP. 
One component of this signaling cascade,Lats1/2, phosphorylates YAP at 
Serine 127, thereby promoting its cytosolic retention and degradation.In line 
with YAP nuclear retention after the treatment, we observed that GF 109203X 
caused an increase of both acetylations and phosphorylations on YAP protein, 
with the exception of P-S127, suggesting a Hippo pathway-independent 
mechanism of action of the identified compound. TEAD is the major 
transcriptional factor partner in the functional activity of YAP and CTGF is 
considered one of the main representative target genes whose expression is 
regulated by this couple of transcriptional regulators.Chromatin 
immunoprecipitation experiments allowed us to demonstrate that GF 109203X 
interferes with YAP binding to CTGF promoter, without affecting the presence of 
TEAD at the same region. This inhibition is responsible of CTGF 
downregulation during GF 109203X administration and it can explain the 
phenotypic effects we observed. These effects, associated with the observed 
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toxicity in pancreatic cancer cells but not in immortalized HPNE cell lines, make 
GF 109203X a potential lead compound to be used in drug development for 
PDAC treatment.  
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INTRODUCTION 
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1. PANACREAS PROJECT 
 
 
In the PANACREAS project, a team composed of clinicians, translational cancer 
researchers, chemists, and two pharmaceutical enterprises (one of them is a 
SME) has been built to synthesize, implement and test new drugs for PDAC. 
 
The final aim consists in synthesizing new molecules, assessing their capacity 
to effectively block precise cancer-associated mechanisms and determining 
their anticancer activity in vivo. Compounds with strong Proof of Concept (PoC) 
activity will be developed up to the Investigational New Drug (IND) stage, and 
thus put on their way to clinical experimentation. 
 
The phases of this project are: 
 
- the synthesis and screening of new targeted inhibitors; 
- the hit-validation and lead optimization phase; 
- pre-formulation/formulation work and PK/BA studies of those compounds that 
appeared promising in terms of in vitro anticancer activity/potency/specificity, at 
the pharmaceutical companies;  
- PoC study in PDAC models at the CIO Cologne-Bonn (where the project 
coordinator is located); 
- IND-enabling study with one or more compounds that show PoC activity in 
these models, in particular those exhibiting an improved efficacy when 
compared to the current standard-of-care gemcitabine, in order to deliver by the 
end of the project a drug that is ready for clinical testing. 
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Our role and tasks 
 
In the frame of this project, the laboratory of Genomic Screening is involved in 
two work packages (WPs). In one of these, the aim is to identify a potential new 
lead molecule that inhibits the Hippo pathway. In order to achieve this target, 
the proposal was to set up an immunofluorescent assay for detecting the 
subcellular localization of nuclear protein YAP. This assay should be used for 
the primary screening in order to evaluate those compounds able to relocate 
YAP protein in the cytoplasm since its cytoplasmic localization is related to the 
loss of its functionality. During my PhD course I have been primary involved in 
this work package, starting from scratch every activity and I have been 
responsible to set up and perform the proposed assay, characterize the 
molecular mechanism of action of the molecular entity identified and evaluate 
the importance of the YAP protein in PDAC cell lines. 
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2. PANCREATIC CANCER 
 
 
Pancreatic cancer is a highly aggressive type of cancer and represents the 7th 
most frequent cause of cancer death worldwide with an approximate 265 000 
deaths, out of 280 000 new cases in 2008 (Ferlay J et al. 2008: GLOBOCAN 
2008). Incidence rates are higher in more high-income areas of the world, 
intermediate in South and Central America and Eastern Asia, and lowest in low-
income areas (Figure 1). Mortality from pancreatic cancer has been increasing 
in high-income countries between the 1950s and the 1980s, and has been 
leveling off or declined (European Union) thereafter, particularly in men.  
 
 
 
 
 
Figure 1. Estimated age-standardized incidence rate per 100,000 pancreas: both sexes, 
both ages _ GLOBOCAN 2008 (ARC) 
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2.1 Future prediction 
 
 
Pancreatic cancer is unique among the top five cancer killers (currently lung, 
colorectal, breast, pancreas and prostate) in that both the incidence rate and 
death rate are increasing (Figure 2). The result of the combination of these 
factors is that both the projected numbers of new pancreatic cancer cases and 
pancreatic cancer deaths will be more than double by 2030. By as early as 
2015, the number of deaths from pancreatic cancer will exceed those from 
breast and colorectal cancer, and be surpassed only by the loss of life from lung 
cancer. 
 
 
 
 
 
 
 
Figure 2. Projected cancer deaths for the major cancer killers.Projections were calculated 
by considering expected changes in the number of new cases for that cancer site and the 
average annual change expected in the death rate (number of deaths/100,000 population). 
Separate values were calculated for men and women and then combined to obtain the value for 
the total population. The projected number of new cases for 2020 and 2030 were calculated 
using age-, sex-, race-, and origin-specific incidence and applying the delay-adjusted average 
annual percent changes in incidence rate calculated by Eheman et al (Cancer 118:2338, 2012). 
These figures were further adjusted by the average annual percent changes in death rate 
calculated by Eheman et al (Cancer 118:2338, 2012, Table 2) _ Pancreatic Cancer Action 
Network 
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2.2 Epidemiology and risk factors 
 
 
Pancreatic adenocarcinoma is generally thought to arise from pancreatic ductal 
cells; however, this remains an area of ongoing study (Hruban RH et al. 2001; 
Meszoely IM et al. 2001). The etiology of pancreatic adenocarcinoma remains 
poorly defined. Risk factors for developing pancreatic cancer include family 
history of the disease, age, chronic or hereditary pancreatitis, smoking, obesity 
and recent-onset diabetes. These and other risk factors are still being 
investigated. Pancreatic adenocarcinoma occurrence is associated with ageing 
(Anderson K et al. 2006), it is rare before the age of 40, it culminates in a 40-
fold increased risk by the age of 80. Moreover, pancreatic cancer is about 30% 
more common in men than in women. The lifetime risk of developing pancreatic 
cancer is about 1.5% for both men and women.Figure 3 is related to the 
pancreatic cancer incidence in the United States, where the disease is a 
relevant problem, representing the fourth leading cause of cancer-related 
death.Examples of modifiable risk factors are: tobacco usage and obesity. 
Tobacco use is the most important known risk factor for pancreatic cancer; 
approximately 20% of pancreatic cancers are attributable to cigarette smoking 
(Iodice S et al. 2008). The risk of developing pancreatic cancer is about twice as 
high among smokers as among never smokers (Anderson K et al. 2006); risk 
increases with greater tobacco use and longer duration of smoking (Bosetti C et 
al. 2012). Obesity has also been fairly consistently linked to increased risk of 
pancreatic cancer. Obese individuals have a 20% higher risk of developing 
pancreatic cancer than those who are normal weight (Berrington de Gonzalez A 
et al. 2003; Arslan AA et al. 2010). At the genetic level, numerous studies have 
documented an increased risk in the relatives of pancreatic adenocarcinoma 
patients (approximately threefold), and it is estimated that 10% of pancreatic 
cancers are due to an inherited predisposition (Lynch, HT et al. 1996). 
However, unlike familial cancer syndromes for breast, colon and melanoma, 
pancreatic adenocarcinoma that is linked to a familial setting has a lower 
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penetrance (<10%) and maintains a comparable age of onset as sporadic 
cases in the general population.  
 
 
 
 
 
 
Figure 3. Pancreatic cancer incidence rates by age and sex (a) and age and race (b), US, 
2005-2009. Source: North America Association of Central Cancer Registries (NAACCR). Data 
are collected by cancer registries participating in NCI’s SEER program and CDC’s National 
Program of Cancer Registries _ American Cancer Society, Surveillance Research, 2013 
 
 
 
 
 
2.3 Molecular genetics of pancreatic adenocarcinoma 
 
 
The pancreatic-duct cell is generally believed to be the progenitor of pancreatic 
adenocarcinoma. As defined in Cubilla and Fitzgerald’s classic study (Cubilla 
AL & Fitzgerald PJ, 1976) the increased incidence of abnormal ductal structures 
(now designated pancreatic intraepithelial neoplasia, PanIN) (Klein WM et al. 
2002) in patients with pancreatic adenocarcinoma, and the similar spatial 
distribution of such lesions to malignant tumors, are consistent with the 
hypothesis that such lesions might represent incipient pancreatic 
adenocarcinoma. Histologically, PanINs show a spectrum of divergent 
morphological alterations relative to normal ducts that seem to represent graded 
stages of increasingly dysplastic growth (Hruban RH et al. 2001) (Figure 4). Cell 
proliferation rates increase with advancing PanIN stages, which is consistent 
with the idea that these are progressive lesions (Klein WM et al. 2002). A 
growing number of studies have identified common mutational profiles in 
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simultaneous lesions, providing evidence of the relationship between PanINs 
and the pathogenesis of pancreatic adenocarcinoma. Specifically, common 
mutation patterns in PanIN and associated adenocarcinomas have been 
reported for K-RAS and for CDKN2A (Moskaluk CA et al. 1997). In addition, 
similar patterns of Loss Of Heterozygosity (LOH) at chromosomes 9q, 17p and 
18q (harboring CDKN2A, TP53 and SMAD4, respectively) have been detected 
in coincident lesions (see below), and studies have consistently shown an 
increasing number of gene alterations in higher-grade PanINs (Yamano M et al. 
2000). Intriguingly, there seems to be an ordered series of mutational events in 
association with specific neoplastic stages. A characteristic pattern of genetic 
lesions in evolving pancreatic adenocarcinoma has been revealed. The field is 
now facing with the challenge of understanding how this signature of genetic 
lesions — mutations of K-RAS, CDKN2A, TP53, BRCA2 and SMAD4/DPC4 — 
contribute to the biological characteristics and evolution of this disease.K-RAS 
is one member of a family of three ras oncogenes that also includes the Harvey- 
and N-ras oncogenes. The ras oncogenes encode for closely related GTP-
binding proteins that can acquire transforming potential when altered in one of 
the critical positions at codons 12, 13, or 61. Under normal circumstances, ras 
proteins are involved in growth signal transduction within the cell, similarly to 
“second messenger” G-proteins (Mc Cormick FR et al. 1995). The mutated K-
RAS encodes a protein locked in a constitutively active state, leading to 
persistent downstream signals such as activation of the RAF-MEK-ERK 
(extracellular signal-regulated kinase) cascade (Roberts PJ and Der CJ. 2007). 
The commonly occurring mutations of K-RAS alter the ability of the K-RAS 
protein to hydrolyse GTP. Thus the K-RAS protein becomes constitutively 
active, persistently stimulating its downstream targets and acting as though 
under constant mitogenic stimulus. In PDAC these mutations occur almost 
exclusively in codon 12 and to a lesser extent in codons 13 and 61. K-RAS 
mutations have been observed in 70–100% of pancreatic cancers. This is the 
highest incidence of K-RAS mutation found in any cancer. Interestingly, mutated 
K-RAS is present in both invasive cells and the earlier non-invasive cells. 
Evidence for this comes from a number of studies (Luttges J et al. 1999). The 
tumor suppressor gene p53 is the most commonly mutated gene in human 
cancer and has been found to be mutated in 50–70% of human pancreatic 
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adenocarcinomas(Pellegata NS et al. 1994). Common types of p53 mutations 
detected in pancreatic tumors include single nucleotide changes, intragenic 
deletions, and microdeletions(Pellegata NS et al. 1994). The protein encoded 
by p53 has a transcriptional regulator role in which it modulates the expression 
of genes involved in cell cycle control, DNA repair, and apoptosis (Levine AJ et 
al. 1997). Cells without active p53 continue to divide and will either die or 
accumulate additional errors. This latter phenomenon may explain why tumor 
cells show a progressive increase in DNA damage, such as deletions, 
translocations, and amplified genes.The p16INK4A/CDKN2A gene, located on 
the short arm of chromosome 9 (9p), is one of the most frequently inactivated 
tumor suppressor genes in PDAC. Virtually all pancreatic carcinomas have loss 
of p16INK4A/CDKN2A function, in 40% of pancreatic cancer through 
homozygous deletion, in 40% by an intragenic mutation coupled with loss of the 
second allele, and in 15% by hypermethylation of the p16INK4A/CDKN2A gene 
promoter (Schutte M et al. 1997). p16 belongs to the cyclin-dependent kinase 
(CDK) inhibitors family and prevents the phosphorylation of cyclin D-CDK4 and 
cyclin D-CDK6 complexes, which in turn inhibit Rb-1 phosphorylation, 
modulating cell-cycle progression. In PDAC, p16INK4A inactivation leads to 
inappropriate phosphorylation of Rb-1, allowing progression of cell cycle 
through the G1/S transition (Sellers WR et al. 1995). DPC4/SMAD4 is a tumor 
suppressor gene on chromosome 18q inactivated in about 55% of the cases of 
PDAC. Inactivation of DPC4/SMAD4 occurs either through homozygous 
deletion, in approximately 30% of the cases, or loss of one allele coupled with 
an intragenic mutation in the second allele in approximately 25% of the events 
(Koorstra JB et al. 2008).SMAD4 is a downstream effector of the transforming 
growth factor-β (TGF-β) pathway that acts in the nucleus as a transcription 
factor promoting growth inhibition and stopping inappropriate G1/S transition 
(Heldin CH et al. 1997). TGF- βs are multifunctional polypeptides that inhibit the 
growth of epithelial cells and exert multiple effects on the extracellular matrix. 
TGF- β1 acts through a family of transmembrane receptors that have intrinsic 
serine/threonine kinase activity. The inhibitory Smads, Smad6 and Smad7, 
associate with the activated TGF-β receptor type I, thereby blocking access and 
phosphorylation of Smad2 and possibly Smad3. This prevents their interaction 
with Smad4, and blocks their subsequent nuclear translocation (Imamura T et 
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al. 1997).Crane et al. studied disease progression and SMAD4 expression in 
locally advanced PDAC in a phase III clinical trial after treatment with 
cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation and 
cetuximab (Crane CH, et al. 2011). The Breast Cancer Type 2 (BRCA2) has 
been implicated in regulation of gene transcription, chromatin remodeling, cell 
growth, DNA damage repair and chromosomal instability (Van der Heijden MS 
et al. 2005). Inherited mutations in the BRCA2 gene caused familial 
breast/ovarian cancer syndrome which is associated with an increased risk of 
breast cancer both in men and women and a subset of these families also have 
an increased risk of PDAC (Berman DB et al. 1996). 7 e 10% of PDAC harbor 
an inactivating intragenic mutation of one copy of the BRCA2 gene, coupled 
with loss of heterozygosity germline mutations of the BRCA2 gene (13q12-13) 
identified in 4 e 17% of familial pancreatic cancer (Naderi A et al. 2002). 
 
 
 
 
 
Figure 4. Genetic progression model of pancreatic adenocarcinoma.Pancreatic 
intraepithelial neoplasias (PanINs) seem to represent progressive stages of neoplastic growth 
that are precursors to pancreatic adenocarcinomas. The genetic alterations documented in 
adenocarcinomas also occur in PanIN in what seems to be a temporal sequence, although 
these alterations have not been correlated with the acquisition of specific histopathological 
features. The stage of onset of these lesions is depicted. The thickness of the line corresponds 
to the frequency of a lesion _ Pancreatic cancer biology and genetics. Bardeesy N, DePinho 
RA. Nat Rev Cancer 2002; 2(12):897-909 
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2.4 Treatments 
 
 
Pancreatic cancer is a leading cause of cancer death largely because there are 
no efficient diagnostic tools for early detection or effective treatment options, 
because of the complex biological features of the disease. Early stage 
pancreatic cancer usually has no symptoms, or only vague disorders that could 
indicate many different conditions within the abdomen or gastrointestinal tract. 
Due to a lack of specific symptoms and limitations in diagnostic methods, the 
disease often eludes detection during its formative stages. When symptoms do 
occur, the tumor has usually spread to surrounding tissues or distant organs. To 
date, there is no single, reliable test for the early detection of pancreatic cancer; 
therefore, screening the general population is not recommended by any health 
agency(Greenhalf W et al. 2009). Existing screening programs have been 
limited to research settings with a focus on detecting precancerous lesions 
among high-risk individuals (Shin EJ et al. 2012). Treatment options for 
pancreatic cancer are limited. In adenocarcinoma, the most common type of 
pancreatic cancer, surgical removal of the tumor is possible in only 
approximately 15% of patients. Postoperative (adjuvant) chemotherapy either 
alone or in combination with radiation has been proven to improve progression-
free and overall survival in both randomized controlled trials and observational 
studies (Neoptolemos JP 2011). The role of radiation therapy by itself in the 
adjuvant setting remains unclear (Abrams RA et al. 2012). Treatment with 
chemotherapy or chemoradiotherapy prior to surgery (neo-adjuvant) is an 
emerging strategy. There are three FDA-approved drugs for the treatment of 
pancreatic adenocarcinoma, and two FDA-approved drugs to treat advanced 
pancreatic neuroendocrine tumors. The treatment for patients with advanced 
disease focuses on managing symptoms and relieving pain and suffering 
(palliative care). Treatment options include chemotherapy alone or in 
combination with radiation. The chemotherapy drug gemcitabine has been a 
standard initial treatment for patients with metastatic pancreatic cancer for more 
than 15 years. However, the National Comprehensive Cancer Network’s 
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Guidelines for the treatment of pancreatic cancer stated that clinical trials are 
the preferred option for treatment. Numerous clinical trials have tested new 
drugs, either alone or in combination with gemcitabine, in these patients. The 
chemotherapy regimen known as FOLFIRINOX is the only treatment that has 
been shown in a clinical trial to improve the survival of patients with metastatic 
pancreatic cancer. In an international randomized phase III trial, patients with 
metastaticpancreatic cancer who were treated with a combination of albumin-
bound paclitaxel (nab-paclitaxel [Abraxane®]) and gemcitabine (Gemzar®) lived 
longer than patients who were treated with gemcitabine alone. Patients who 
received both drugs also lived longer without their disease getting worse 
(progression-free survival). Nab-paclitaxel is a form of the chemotherapy drug 
paclitaxel that is bound to the human protein albumin and contained in 
nanoparticles. Binding paclitaxel to albumin eliminates the need for solvent that 
keep paclitaxel soluble once injected into the body but that can also cause 
allergic reactions and side effects. Albumin also plays a key role in delivering 
nutrients to dividing cells. Tumor cells require an abundance of nutrients to 
survive, so binding paclitaxel to albumin helps deliver paclitaxel to tumor cells. 
Studies in mice with tumors derived from human pancreatic cancer cells 
suggested that the combination of gemcitabine and nab-paclitaxel was more 
effective than either drug alone. Results from a phase I/II trialstrongly suggested 
that the combination could be effective in previously untreated patients with 
metastatic pancreatic cancer (Von Hoff DD et al. 2013). 
 
 
3. YAP 
 
 
 
Marius Sudol and colleagues in 1995 characterized a novel protein: the Yes-
associated protein, YAP (Sudol M et al. 1995). YAP protein consists of 454 
amino acids, with a molecular weight of 65 kDa (Sudol M et al. 1994).YAP has a 
proline-rich (P-rich) region at the N-terminal, two tandem WW domains in the 
middle followed by an Src homology domain 3 binding motif (SH3 BM) 
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PVKQPPPLAP, a coiled-coil domain (CC), and a C-terminal capped by TWL 
sequence, a PDZ domain ligand.The proline-rich region is responsible of the 
interaction with SH3 domains of c-Yes and many other proteins. The WW 
domain contains two tryptophan residues, which appear to be conserved along 
evolution and that play an important role in the domain structure and function 
(Sudol M et al. 1995; Sudol M and Hunter T 2000). This domain binds to short 
stretches of prolines (PY motif), and therefore mediating the interaction between 
proteins. YAP has been found to interact with many proteins, whose function 
often is quite substantially different, and the majority of these interactions is 
mostly mediated by the WW domain (Bertini et al. 2009).The N-terminal of YAP 
was mapped to be the TEAD family transcription factors interaction domain, and 
the C-terminal of YAP rich in serine, threonine, and acidic residues was shown 
to be a strong transcription activator.The human YAP1 coding sequence 
consists of 1364 bp from the start codon to the stop codon. A differentially 
spliced isoform of YAP1 (9 exons), with two WW domains known as YAP2 also 
exists (Sudol M et al. 1995). Regulation of the switch between the two YAP 
isoforms is not clear. In general, YAP mRNA is ubiquitously expressed in a wide 
range of tissues, except peripheral blood leukocytes (Komuro A et al. 2003). 
YAP is also expressed in the full developmental stages from blastocyst to 
perinatal (Morin-Kensicki EM et al. 2006). However, the function of YAP 
remained enigmatic until it was shown to be a transcription co-activator (Yagi R 
et al. 1999). YAP does not have any obvious DNA binding domain. However, 
when fused to Gal4 DNA binding domain, YAP could strongly activate 
luciferase, therefore, it is categorized as a transcription co-activator. The 
transcription activation domain of YAP was further mapped to the C-terminal 
region. Interestingly, this region was found to be truncated in possibly dominant-
negative YAP isoforms specifically expressed in neurons (Hoshino M et al. 
2006). YAP interacts with the PPXY (Proline-Proline-x–Tyrosine) motif of 
transcription factor PEBP2α (RUNX1 and RUNX2). Peptide ligand containing 
PPXY consensus motif is specific for binding WW domain. Besides that, YAP 
has also been reported to co-activate other PPXY-motif-containing transcription 
factors, including ErbB4 cytoplasmic domain (Komuro A et al. 2003) and p73 
(Strano S et al. 2001). YAP also binds to TEAD family transcription factors 
(Vassilev A et al. 2001), which have four highly homologous proteins sharing a 
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conserved DNA-binding TEA domain, found in N-terminal of particular gene 
regulatory proteins, in human and mouse (see below). TAZ (transcriptional co-
activator with PDZ-binding motif) is also referred to as WWTR1 (WW domain 
containing transcription regulator 1). TAZ is homologous to YAP with 46% 
amino acid sequence identify (with YAP isoform 3) and displaying similar 
domain organization but having only one WW domain. Both YAP and TAZ are 
homologous to fly Yki, which was identified as a downstream target of the Hippo 
pathway in 2005 (Huang J et al. 2005) (Figure 5). 
 
 
 
 
Figure 5. A schematic view of YAP, TAZ, and Yki.YAP has a proline-rich (P- rich), two 
tandem WW domains in the middle, followed by a Src homology domain 3 binding motif (SH3 
BM) PVKQPPPLAP, a coiled-coil domain (CC), and a C-terminal capped by TWL sequence, a 
PDZ domain ligand. The N-terminal (aa 47-154 in human YAP2, shaded in blue) of YAP was 
mapped to be the TEAD family transcription factors interaction domain, and the C-terminal of 
YAP (aa 292-488, shaded in pink) rich in serine, threonine, and acidic residues was shown to 
be a strong transcription activator. The Lats phosphorylation and 14-3-3 binding critical S127 in 
human YAP2 and its equivalent in Yki and TAZ are also shown. The topology of Yki and TAZ 
are shown in similar fashion and the proteins are drawn in scale _ The Hippo-YAP pathway: 
new connections between regulation of organ size and cancer. Zhao B et al. Curr Opin Cell Biol 
2008; 20(6):638-46.  
 
 
 
 
 
 
3.1 REGULATION 
 
 
3.1.1. Hippo pathway 
 
 
The Hippo signaling pathway was initially defined by genetic studies in 
Drosophila to regulate tissue growth and organ size and is highly conserved in 
mammals (Zhao B et al. 2010) (Figure 6). The Hippo core kinase cassette 
	   24	  
contains four proteins, two of which are kinases: Hpo and Wts in the fly and 
Mst1/2 and Lats1/2 in mammals. The other two proteins, Sav and Mats in the 
fly, and WW45 and Mob in mammals, act as adaptors/activators. In mammals, 
Mst1/2 in association with WW45 is activated by phosphorylation in response to 
upstream regulators. The activated Mst1/2-WW45 can phosphorylate and 
activate LATS1/2-Mob complex. The major target of the Hippo core kinase 
cascade is Yki transcription co-activator in the fly and YAP and TAZ in 
mammals. Mechanistically, Mst2 and LATS2 were shown to act coordinately to 
phosphorylate YAP at HXRXXS motifs, which is defined as a Lats recognition 
motif, with the S127-containing motif being the major site whose 
phosphorylation created a binding site for 14–3–3 proteins. TAZ and Yki have a 
corresponding motif with S89 and S168 as the major site, respectively. 
Phosphorylation of YAP and TAZ by the Hippo pathway leads to their 
sequestration in the cytoplasm by interaction with 14–3–3 proteins and 
ubiquitination-dependent proteasomal degradation. Therefore, the Hippo 
pathway acts to restrict the availability/functionality of YAP and TAZ in the 
nucleus by governing its distribution and protein levels. In the fly, Yki binds 
Scalloped (Sd) and activates transcription of downstream target genes like 
Diap, bantam and cycE. In mammals, YAP and TAZ interact primarily with 
transcriptional factors TEAD1–4 (TEADs) and activate expression of target 
genes such as CTGF, IGFBP3, ITGB2, Birc5/Survivin, Gli2, and Axl. 
 
 
Figure 6. The Hippo pathway in Drosophila and mammals.Corresponding components in 
Drosophila and mammals are shown in the same color. The abbreviations used are as follows: 
Ex (Expanded), Mer (Merlin, also called NF2), Hpo (Hippo), Sav (Salvador), Mats (Mob as 
tumor suppressor), Wts (Warts), Yki (Yorkie), Sd (Scalloped), Mst (Mst1/2, also called STK4 
and STK3, Hpo homolog), WW45 (Sav homolog), Mob (Mps One Binder kinase activator-like 
1A/B, MOBKL1A/B, Mats homolog), Lats (Lats1/2, Wts homolog), YAP (Yes-associated protein, 
Yki homolog), TAZ (transcriptional co-activator with PDZ-binding motif, also called WWTR1, Yki 
homolog), and TEAD (TEA domain family member 1/2/3/4). Dashed arrows indicate unknown 
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biochemical mechanism and question marks denote unknown components _ The Hippo-YAP 
pathway: new connections between regulation of organ size and cancer. Zhao B et al. Curr 
Opin Cell Biol 2008; 20(6):638-46. 
3.1.2. Cell density / Cell contact 
 
 
A fundamental property of a normal cell is to cease proliferation upon reaching 
confluence, a phenomenon referred to as cell contact inhibition (Eagle H and 
Levine EM 1967). In contrast, cancer cells are able to escape cell contact 
inhibition, which enhances their ability to invade host tissues and metastasize 
(Hanahan D and Weinberg RA 2000). Several lines of evidence support the 
function of YAP in mediating cell contact inhibition. First, cell density regulates 
Lats kinase activity and YAP nuclear/cytoplasmic shuttling. The Hippo pathway-
induced phosphorylation of YAP is utilized in YAP regulation by cell density and 
is likely conserved in Drosophila. At low density, YAP is predominantly localized 
in the nucleus. In contrast, YAP translocates to the cytoplasm at high density. 
This phenomenon was observed in different cell lines, such as in the MCF10A 
human breast epithelial cells and in NIH-3T3 murine embryonic fibroblast (Zhao 
B et al. 2007). Second, scratching of confluent cultured cells induces YAP 
nuclear localization in cells at the wound edge. Those cells with nuclear YAP 
also enter the cell cycle. Third, YAP-overexpressing cells fail to exit the cell 
cycle when confluent and grow to a much higher density. Fourth, expression of 
dominant-negative YAP restores contact inhibition in a human cancer cell line 
bearing deletion of Sav. Fifth, YAP regulates many genes in a manner opposite 
to high cell density. Furthermore, YAP is inhibited by Merlin, which has been 
implicated in mediating cell contact inhibition (Okada T et al. 2005). 
 
Epithelial cells usually adhere to one another through cell–cell junctions such as 
adherens junctions (AJs), desmosomes, and tight junctions (TJs) (Figure 7). 
TJs and AJs, with help from different polarity complexes, divide the plasma 
membrane into an apical domain and a basolateral domain and thereby 
establish an apical–basal polarity in epithelial cells (Martin-Belmonte F and 
Perez-Moreno M 2012). Interestingly, many upstream regulators identified for 
the Hippo pathway are known components of TJs, AJs, or apical–basal polarity 
protein complexes. In Drosophila, Mer, Ex, and Kibra colocalize at the apical 
domain of polarized epithelial cells (Yu et al. 2010) and this complex may recruit 
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the Hippo pathway kinases to the apical plasma membrane for activation 
(Genevet et al. 2010). The regulation of apical–basal polarity on the Hippo 
pathway is largely conserved in mammals. Disruption of TJs or AJs in cultured 
mammalian cells causes induction of YAP/TAZ nuclear localization and target 
gene expression (Varelas et al. 2010). Moreover, Scrib also positively regulates 
the Hippo pathway kinases, and downregulation of Scrib leads to YAP/TAZ 
activation (Cordenonsi et al. 2011). In addition, many cell junction proteins, such 
as LIN7C, PATJ, MPDZ, PTPN14, angiomotin (AMOT), and α-catenin, have 
also been identified as interacting partners of core Hippo pathway components 
(Varelas et al. 2010). 
 
 
- Angiomotin 
 
 
AMOT proteins, a family of proteins including AMOT, AMOTL1, and AMOTL2, 
interact extensively with multiple TJ components and are important for 
maintaining TJ integrity and epithelial cell polarity (Wells et al. 2006). Three 
independent studies have recently identified Angiomotin (Amot), Angiomotin-like 
1 (AmotL1) and Angiomotin-like 2 (AmotL2) as negative regulators of YAP and 
TAZ (Zhao B et al. 2011). The AMOT–YAP/TAZ interaction is not dependent on 
the YAP/TAZ phosphorylation status and is instead mediated by AMOT PPxY 
motifs and YAP/ TAZ WW domains (Chan SW et al. 2001; Zhao B et al. 2011). 
AMOT proteins recruit YAP/TAZ to TJs or the actin cytoskeleton, which 
consequently results in reduced YAP/TAZ nuclear localization and activity. In 
addition, AMOT proteins also induce YAP/TAZ phosphorylation at Lats target 
sites; this might be due to a scaffolding function of AMOT on Hippo pathway 
components such as MST2, Lats2, and YAP (Paramasivam M et al 2011). 
AMOT proteins can therefore inhibit YAP/TAZ activity by both phosphorylation-
dependent and phosphorylation-independent mechanisms. Interestingly, AMOT 
has been shown to interact with NF2 and is required for tumorigenesis caused 
by NF2 deficiency (Yi C et al. 2011). Since Amot family proteins are integral 
components of cell junction complexes, their interaction with YAP and TAZ may 
play a key role in regulating the Hippo pathway in response to cell contact in 
vitro and organ size control in vivo.  
	   27	  
 
−  α-catenin 
 
 
α-catenin is an actin binding protein that bridges the cytoskeleton to cell surface 
adhesion molecule cadherin. α-catenin is also found to interact with and inhibit 
YAP and phosphorylation at YAP S127, and subsequent 14-3-3 binding is 
critical for this association in cells (Schlegelmilch K et al. 2011). In fact α-
catenin accomplishes these functions by modulating interaction with 14–3–3 
and PP2A phosphatase. Therefore, α-catenin acts in a manner similar to AMOT 
to inhibit YAP/TAZ. Given the fact that α-catenin is associated with adherent 
junction and AMOT is associated with tight junction, these two proteins may 
relay the cell-cell contact signals to inhibit cell growth via modulating YAP/TAZ. 
 
 
Several other proteins important in establishing or maintaining apical–basal 
polarity have been shown to modulate the Hippo pathway. These data indicate 
that cell–cell contact, integrity of cell junctions, and apical–basal polarity are 
important in regulation of the Hippo pathway. Apical–basal polarity can regulate 
the Hippo pathway by either recruiting the Hippo pathway kinases to the apical 
domain for activation or sequestering Yki/YAP/TAZ at cell junctions, both 
resulting inactivation of YKi/YAP/ TAZ. However, it is worth noting that the 
cellular localization of YAP is mainly in the cytoplasm and nucleus (Zhao B et al. 
2011); the interaction between cell junctional proteins and YAP/TAZ may not 
result in a predominant localization of YAP/TAZ at the cellular apical domain. 
 
 
3.1.3 G-protein-coupled receptor (GPCR) signaling 	  	  
A large number of growth factors regulate cell proliferation by activating 
membrane receptors and intracellular signaling pathways, so it is reasonable to 
speculate that the YAP/TAZ oncoproteins are regulated by growth factors. In 
mammals, the potential identity of extracellular ligands and their cognate 
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receptors that regulate the Hippo pathway remained elusive until recently. Two 
independent groups have reported that serum could rapidly activate YAP/TAZ in 
cultured cells. By extensive biochemical analysis, lysophosphatidic acid (LPA) 
and sphingosine 1-phosphate (S1P) were identified as the major components in 
serum responsible for YAP/TAZ activation (Yu FX et al. 2012). Both reports 
showed that LPA or S1P bound to their corresponding membrane GPCRs and 
act through Rho GTPases to activate YAP/TAZ. Consistently, another report 
showed that thrombin, which activates protease-activated receptors (PARs; a 
GPCR), also stimulated YAP/TAZ activity via Rho GTPases (Mo et al. 2012). 
These results suggest that YAP/TAZ can be regulated by diffusible extracellular 
signals and cell surface receptors. Yu et al. further showed that YAP/TAZ is 
regulated by many GPCRs and their cognate ligands and established a general 
function of GPCR in YAP/TAZ regulation. GPCRs usually activate downstream 
signaling through heterotrimeric G proteins. Ga12/13-, Gaq/11-, or Gai/o-
coupled signals induce YAP/TAZ activity, whereas Gas-coupled signals repress 
YAP/TAZ activity.  
 
 
 
 
 
Figure 7. The role of cell contact in YAP regulation.Many Hippo pathway proteins reside, at 
least partially, at the sub-apical region, adherens junction (AJ) or thigh junctions. Examples of 
such junctional proteins include, in mammals, angiomotin and α-catenin _ The Hippo pathway. 
Kieran F et al. Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a011288.  
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3.2 POST TRANSLATIONAL MODIFICATIONS 
 
 
3.2.1 Phosphorylation 
 
 
The functions of YAP are regulated by multiple post-translational modifications 
(PTMs). The Hippo pathway can negatively regulate TAZ and YAP by two 
different mechanisms through cytoplasmic sequestration and proteasomal 
degradation (Figure 8). Upon activation, the core components of the Hippo 
pathway phosphorylate TAZ and YAP at multiple sites harboring the HXRXXS 
motif. When phosphorylated, phospho-Ser89 of TAZ and phospho-Ser127 of 
YAP serve as the binding sites for 14-3-3 proteins. Accordingly, S89A and 
S127A mutants are largely refractory to this inhibition and are mainly distributed 
in the nucleus (Lei QY et al. 2008; Zhao B et al 2009; Zhao B et al. 2007). Other 
studies also revealed that the Hippo pathway can regulate the stability of YAP 
and TAZ (Liu CY et al. 2010; Zhao B et al. 2010). Phosphorylation of Ser381 of 
YAP and Ser314 of TAZ by the Hippo pathway primes YAP and TAZ, 
respectively, for subsequent phosphorylation by casein kinase 1, leading to their 
ubiquitination and proteasomal degradation. Chan et al. presented another 
novel mechanism of regulation of TAZ and YAP function through direct 
interaction with Amot and AmotL1, leading to their cytoplasmic sequestration 
that is independent of Hippo pathway-regulated interaction with 14-3-3 proteins 
(Chan W et al. 2011). The general working model is that Amot and AmotL1 
(likely also AmotL2) are primary cytosolic proteins that interact with TAZ and 
YAP through the first PPXY motif of Amot and AmotL1 and the WW domain of 
TAZ and YAP. This interaction causes cytoplasmic sequestration of TAZ and 
YAP in a manner similar to but independent of TAZ-YAP interaction with 14-3-3 
proteins. In the case of YAP, it is intriguing to note that first but not the second 
WW domain is important for interaction with Amot and AmotL1. Because Amot 
has been shown to be distributed to the junctional complexes of polarized 
epithelial cells (Wells CD et al. 2006), it is also possible that Amot and AmotL1 
may mediate localization of TAZ and YAP to the cell junction in polarized 
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epithelial cells (described above). 
 
 
Figure 8. A working model for diverse regulatory mechanisms for TAZ and YAP.The 
Hippo pathway causes cytoplasmic sequestration of TAZ and YAP through phosphorylation of 
Ser89 and Ser127, respectively. Furthermore, Hippo pathway-mediated phosphorylation of 
Ser314 and Ser381 leads to further phosphorylation, ubiquitination, and proteasomal 
degradation of TAZ and YAP, respectively. Interaction with TEADs is important for nuclear 
accumulation and transcriptional outcome of TAZ and YAP. Amot and AmotL1 (likely also 
AmotL2) function as negative regulators of TAZ and YAP through direct interaction with the WW 
domain of TAZ and the first WW domain of YAP via the first PPXY motif of Amot and AmotL1 
that is also conserved in AmotL2, leading to their cytoplasmic retention _ Hippo Pathway-
independent Restriction of TAZ and YAP by Angiomotin. Siew Wee Chan et al. J. Biol. Chem. 
2011, 286:7018-7026. 
 
 
3.2.2 Acetylation 
 
 
Hata and co-workers recently reported a novel cycle of acetylation/deacetylation 
of nuclear YAP induced in response to SN2 alkylating agents (Figure 9). These 
agents but not other DNA-damaging stimuli are able to reduce YAP S127 
phosphorylation mediated by Hippo pathway, leading to nuclear translocation of 
YAP and its acetylation (Hata S et al. 2012). The nuclear acetyltransferases 
CBP and p300 are reasonable of YAP acetylation that specifically occurs on 
specific and highly conserved C-terminal lysine residues: K494 and K497.In 
previous reports, CBP and p300 were shown to directly acetylate a variety of 
proteins at a consensus motif [KX1-2(X/K)K] (Wang C et al. 2001). Notably, 
hYAP contains this consensus motif (K494LDK497), and the YAP acetylation 
sites identified are consistent with the positions of two of the lysine residues 
present in this motif. Interestingly, this consensus motif is not found in either Yki 
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or in TAZ (Zhao B et al. 2001b), thus the CBP/p300-dependent acetylation 
appears to be a modification specific to vertebrate YAP. Conversely, the nuclear 
deacetylase SIRT1 is responsible for YAP deacetylation. Importantly, 
acetylation of YAP influences both its transcriptional co-activator activity and the 
sensitivity of YAP-expressing cells to MMS-induced DNA damage. However 
authors indicate that mere nuclear accumulation of hYAP is not enough to 
induce its acetylation, and other factors must play an important role in this 
reaction. 
 
 
 
 
 
Figure 9. A proposed model for hYAP regulation in response to SN2 alkylating 
agents.Cell-cell contact triggers Hippo pathway signaling that up-regulates S127 
phosphorylation of hYAP and thus its cytoplasmic retention via binding to 14-3-3 protein. SN2 
alkylating agents damage DNA, leading to a reduction in S127 phosphorylation of hYAP. Non-
phosphorylated hYAP is released from the cytoplasmic 14-3-3 complex and translocates into 
the nucleus. Within the nucleus, CBP and/or p300 activated by SN2 alkylating agent-mediated 
DNA damage induce hYAP acetylation at K494 and K497. Concurrently, deacetylation of these 
residues is mediated by SIRT1. Thus, tight regulation governs the state of hYAP acetylation 
induced in response to SN2 alkylating agents _ A novel acetylation cycle of the transcription co-
activator Yes-associated protein that is downstream of the Hippo pathway is triggered in 
response to SN2 alkylating agents. Hata S et al. J Biol Chem 2012;287(26):22089-98. 
 
 
 
 
3.2.3 Ubiquitination 
 
 
Ubiquitination is mostly catalyzed by the sequential action of three enzymes 
namely, E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzymes), 
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and E3 (ubiquitin ligase). E3 determines substrate specificity, and its substrate 
binding is the primary event controlling the stability of a particular protein 
(Pickart CM 2001). The adaptor protein Amot130 is shown to scaffold a 
complex containing overexpressed atrophin-1 interacting protein 4 (AIP4) and 
YAP. Consequently, Amot130 promotes the ubiquitination of YAP by AIP4 and 
prevents AIP4 from binding to Lats1, thus reducing YAP stability and inhibiting 
cell growth (Adler et al. 2013).  
 
 
 
3.3 DUAL ROLE OF YAP 
 
 
It is extremely difficult to include the biological consequences of YAP activity 
into a unique category. Since its ability to activate apoptosis YAP can be 
considered a tumor suppressor gene. On the other hand, a huge amount of 
data suggest the possibility that YAP may indeed be an oncogene, thus 
supporting the findings that come from Drosophila for the conservation of the 
Hippo pathway. Finally, YAP is defined as a key component of the molecular 
machinery that drives cell differentiation and regulates organ size. All its 
conflicting functions support the idea that YAP is placed at the crossroads of 
many signalling pathways, where it plays a role depending on the upstream 
stimuli and the binding to its multiple targets. The context appears to be crucial, 
for example the origin of the cell and the kind of cell line (primary, immortalized, 
or fully cancerous). In any case, the importance of PTMs in the regulation of 
YAP is clear (described above). More work therefore has to be done if we want 
to clarify the role that this protein plays during normal cell life and on the onset 
of cancer. 
 
 
3.3.1 Yap as a tumor suppressor gene  
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Among all proteins found to interact with YAP, the group of Giovanni Blandino 
found YAP1 to be able to bind through its WW domain to a PY motif present on 
the C-terminal region of p73. The binding to p73 causes an increment in the 
transcriptional ability of p73 supporting the possible involvement of YAP in the 
induction of apoptosis (Strano S et al. 2001). Further works showed how, 
following DNA damage, p73 and YAP1 associate into the nucleus with p300 
and PML, forming a proapoptptic autoregulatory feedback loop. PML is 
responsible for the sub-nuclear localization of the p73-YAP1 complex in the 
PML bodies, a dot-looking arrangement of proteins and DNA that appears to be 
involved in transcriptional regulation. The binding between YAP and p73 is 
negatively regulated by Akt-mediated YAP phosphorylation (Basu S et al. 2003) 
and enhanced by DNA damage (Strano S et al. 2005). Upon DNA damage this 
complex recruits the acetyl transferase p300 and together sit onto the regulatory 
regions of pro-apoptotic genes and upregulate their transcription (Lapi E et al 
2008). When YAP1 associates with p73 it increases the stability of the latter, by 
competing with the ITCH E3-ligase, thus preventing p73 disposal by 
proteasome degradation and thus propelling further transcription of pro-
apoptotic genes. Collectively, these observations do not classify YAP as a real 
tumor suppressor, but as a transcriptional co-activator, able to directly or 
indirectly regulate different tumor suppressor pathways (for example p53 family 
or PML). Conversely, when YAP promotes the activation of transcription factors 
whose gene targets encode for oncogenic proteins, its effects are anti-apoptotic 
and pro-proliferative. 
 
 
3.3.2 Yap as an oncogene 
 	  
Despite the evidences underlining YAP as a tumor suppressor (Yuan M et al. 
2008), YAP is also a potent growth promoter. Functions of YAP in organ size 
regulation and tumorigenesis have been confirmed in mammals, using 
transgenic mouse models (Camargo FD et al. 2007; Dong J et al. 2007). 
Human colorectal cancers and other types of cancer expressing higher levels of 
YAP1 share molecular aspects with YAP1-induced dysplastic growth in the 
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mouse (Camargo FD et al. 2007). Moreover, YAP overexpression in MCF10A 
cells induces epithelial-mesenchymal transition (EMT), which is often 
associated with cancer metastasis (Overholtzer M et al. 2006); YAP also 
cooperates with myc oncogene to stimulate tumor growth in nude mice (Zender 
L et al. 2006); and more interestingly, transgenic mice with liver-specific YAP 
overexpression show a dramatic increase in liver size and eventually develop 
tumors (Camargo FD et al. 2007; Dong J et al. 2007). The oncogenic function of 
YAP is further supported by the tumor suppressor function of its inhibitory 
upstream Hippo pathway components. For example, Lats1 knockout leads to 
soft-tissue sarcoma and ovarian tumor development (St John MA et al). Loss-
of-function mutation of WW45 has been observed in several human cancer cell 
lines (Tapon N et al. 2002).  
 
 
 
3.3.3 Organ size  
 
 
The role of YAP in controlling cell proliferation, and thus organ size, has been 
reported also at the physiological level (George NM et al 2012). The 
mammalian pancreas is a dual-function organ critical for the regulation of basic 
metabolism. In the mouse, development of the pancreas is divided into two 
stages. Hippo signaling becomes functionally active during the secondary 
transition, characterized by robust proliferation and differentiation, and plays a 
crucial role in determining overall pancreas architecture, likely through 
downregulation of YAP-dependent cell proliferation. Very early in pancreas 
development, expression of YAP is turned off following specification of 
endocrine fate, potentially explaining the poor proliferation capacity displayed by 
these cells (Pictet RL et al. 1972). Hippo pathway components are important in 
controlling organ size, through YAP regulation. For example, Mst1 and Mst2 
double knockout in liver has been reported to largely abolish YAP 
phosphorylation, and induced an enlarged liver phenotype strikingly similar to 
YAP overexpression (Zhou D et al. 2009; Lu L et al. 2010). However, this effect 
on organ size is more dramatic in some organs, such as liver and stomach, than 
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in others, such as kidney and limb, which do not show an increase in size (Song 
H et al. 2010). This is possibly due to an organ-specific contribution of impaired 
cell differentiation versus cell number on the overall size of the organ. 
Furthermore, the function of Mst1/2 in the Hippo pathway is likely to be cell 
context-dependent, since Mst1/2 are not required for Lats1/2 phosphorylation 
and cell density-induced YAP nuclear–cytoplasmic translocation in mouse 
embryonic fibroblast (MEF) cells (Zhou D et al. 2009), or YAP phosphorylation 
in early embryos. 
 
 
3.3.4 Senescence and cell proliferation 
 
 
On the other hand YAP has been demonstrated to play an important role in the 
maintenance of cell proliferation and resistance to cellular senescence. The 
YAP-TEAD signalling pathway has been reported to partially depend on p16 
and p53 and to regulate CDK6 expression (Xie Q et al. 2013). Moreover YAP 
expression is closely correlated with senescence. In particular, YAP down-
regulation increased senescence in a colorectal carcinoma HCT116 cell line in 
a p53 and p21 dependent manner (Vigneron AM and Vousden KH 2012). 
 
 
 
3.4 INTERACTORS 
 
 
 
Depending on the partner bound, YAP can exert different functions, in different 
tissue and/or under different conditions (Bertini E et al. 2009; Liu AM et al. 
2010) (Figure 10). Despite a major role for TEADs in YAP/TAZ function 
(described below), other transcription factors containing PPXY motifs are known 
to interact with the WW domains of YAP/TAZ. These include Smad1, RUNX, 
ErbB4 and p73 for YAP (Strano,S. et al. 2001;  Komuro A et al. 2003; Alarcon C 
et al. 2009). YAP, TAZ and Yki also induce many other genes directly or 
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indirectly. In mammals, YAP and TAZ induce the expression of AREG118 and 
FGF1 (Zhang J et al. 2009), which may mediate non-cell-autonomous functions 
of the Hippo pathway. However, the mechanisms underlying the induction of 
these genes, including the responsible transcription factors, are mostly unclear. 
 
 
 
 
Figure 10. Summary of proteins shown to interact with YAP/TAZ/Yki. Amot family proteins 
are present only in mammalian cells but the drosophila expanded has been shown to interact 
with WW domain of fly Yki. The potential factors that interact with the C-terminal transactivation 
domain to promote transcriptional program are yet to be defined. The C-terminal PZD-binding 
motif is specific for YAP and TAZ but not present in Yki and has been shown to interact with 
ZO2 and NHERF2. Not all proteins interact with YAP at the same time. In fact, some interaction 
may be mutually exclusive. For example, the 14–3–3 associated YAP would be in cytoplasm 
whereas the TEAD associated YAP should be nuclear _ The YAP and TAZ transcription 
coactivators: key downstream effectors of the mammalian Hippo pathway. Hong W and Guan 
KL. Semin Cell Dev Biol 2012; 23(7):785-93.  
 
 
 
3.4.1 TEAD 
 
 
The TEAD family transcription factors were found to be critical partners of YAP 
and TAZ in the regulation of gene expression (the Drosophila TEAD homologue 
Scalloped (Sd) is partner of Yki) (Zhao B et al. 2008; Goulev Y et al. 2008) 
(Figure 11).An interesting twist in the study of YAP/TAZ/Yki cellular function 
was the identification of YAP as an interacting protein for TEAD2 transcriptional 
factor, which does not have the PPXY motif found in other YAP interacting 
transcription factors (Vassilev A et al. 2001). The C-terminal half of TEAD2 was 
mapped to be responsible for interaction with YAP. In view of the fact that 
TEAD2, together with TEAD1, TEAD3 and TEAD4 form a homologous TEAD 
family, YAP was shown to interact also with TEAD1, TEAD3 and TEAD4 
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(Vassilev A et al. 2001). Importantly, TEAD-mediated transcription was 
dependent on YAP and YAP-TEAD complex can bind DNA containing TEAD-
binding elements. Knockdown of TEADs or disruption of the YAP–TEAD 
interaction abolishes YAP-dependent gene transcription and largely diminishes 
YAP-induced cell proliferation, oncogenic transformation and the epithelial-to-
mesenchymal transition (EMT) (Zhao B et al. 2008; Zhang H et al. 2009).S94 in 
YAP is important for interaction with TEADs and mutation of this residue 
abolished most if not all property of YAP in promoting cellular transformation 
and mediating the transcriptional outcome, suggesting that interaction with 
TEADs is the major functional pathway of YAP. Congruent with this, YAP and 
TEAD bind to a common set of genomic targets. Several direct target genes of 
YAP–/TAZ–TEAD and Yki–Sd have been identified, including CTGF and Cyr61 
in mammalian cells (Zhao B et al. 2008; Lai D et al. 2011).  
 
 
 
 
 
Figure 11.  Domain organization of TEADs.The N-terminal region of TEADs contains the 
highly conserved TEA domain responsible for interaction with DNA elements such as GGAATG 
in the promoter region of target genes (such as CTGF). The amino acid alignment of the TEA 
domain of TEAD1–4 is also shown. The TEA domain forms a 3-helix bundle and the regions for 
the three helices are indicated on top. The nuclear localization signal is indicated below the 
alignment. The C-terminal region of TEADs is responsible for interaction with YAP/TAZ/Yki. 
Three residues conserved in TEADs that were experimentally demonstrated (using mouse 
TEAD4 in the study) to be important for interaction with YAP/TAZ/Yki (using mouse YAP as an 
interacting partner) are indicated (T1–T4 for TEAD1–4; T4m for mouse TEAD4) _ The YAP and 
TAZ transcription coactivators: key downstream effectors of the mammalian Hippo pathway. 
Hong W and Guan KL. Semin Cell Dev Biol 2012; 23(7):785-93. 
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3.5 YAP TARGET GENE: CTGF 
 
 
 
The connective tissue growth factor CTGF is a member of the CCN (CTGF, 
Cyr61, and Nov) family of proteins that promote angiogenesis, cell migration, 
and cell adhesion (Brigstock DR 1999). CCN proteins are now recognized as 
matricellular proteins which function as integral but non-structural components 
of the extracellular matrix (ECM) that modulate cellular responses to other 
molecular cues in the pericellular environment by interacting with integrins, 
HSPG or other receptors on the cell surface such as LRP or the TrkA 
neurotrophin receptor (Rachfal AW and Brigstock DR 2005). A role for CTGF in 
pancreatic development and morphogenesis was first suggested by its 
detection in the mouse pancreas at E14.5 (Surveyor GA and Brigstock DR 
1999). The pancreas has both endocrine and exocrine functions. The endocrine 
component is organized as the islets of Langerhans which comprise 1–2% of 
the pancreatic mass and contain several cell types that secrete distinct products 
(Prado CL et al. 2004). CTGF has been shown to regulate islet morphogenesis 
and function during embryogenesis, and it is both required and sufficient to 
induce proliferation of embryonic b cells (Crawford LA et al. 2009). Several 
evidences revealed a role of CTGF in pancreatic cancer. In one approach, 
CTGF has been studied as a product of the tumor cells which are characterized 
by activation mutations in the K-RAS proto-oncogene during a pre-invasive 
state termed pancreatic intraepithelial neoplasia (PanIN) and, in invasive PDAC. 
In another approach, studies have focused on the contribution of CTGF to the 
desmoplastic reaction which involves the intense production of an interstitial 
stroma that can contribute up to 80% of the tumor mass and comprises 
fibroblasts, myofibroblasts, inflammatory cells and PSC that are associated with 
a highly expanded ECM. This reaction is considered a reservoir of ECM-
associated growth factors that functions dynamically to sustain tumor growth 
and increase its invasive potential (Korc M 2007). Clinical specimens of 
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pancreatic cancer express elevated levels of CTGF mRNA that are 40–60-fold 
greater than normal pancreas and well correlated with the extent and intensity 
of desmoplasia (Wenger C et al. 1999). Studies ofCTGF expression and 
promoter activity have established that MEK/ERK drives basal CTGF production 
in Panc-1 pancreatic tumor cells in a Smad-independent manner as well as in 
other pancreatic cancer cell lines that have defective Smad signaling. On the 
other hand, in pancreatic tumor cell lines that are TGF-β-responsive, CTGF 
production is dependent on the type I TGF-β receptor and MEK/ERK (Pickles M 
and Leask A 2007; Kwon S et al. 2007). Other pathways of CTGF gene 
transcription have been described in PDAC, including their induction as 
immediate early genes in human pancreatic tumor cells in response to 
epidermal growth factor or transforming growth factor-alpha (Wenger C et al. 
1999). Moreover CTGF has been also identified in a metastasis-related gene 
cluster in PDAC neoplastic epithelium (Ryu B et al. 2001). Incubation of Panc-1 
cells in vitro with recombinant CTGF stimulates cell proliferation in monolayer 
culture as well invasion in a Matrigel assay (Aikawa T et al. 2006). Knock-down 
of CTGF mRNA expression has shown to inhibit anchorage-independent growth 
of pancreatic tumor cells in vitro (Bennewith KL, et al. 2009) and, conversely, 
transfection of the cells with human CTGF cDNA is able to enhance it 
(Dornhofer N et al. 2006). Notably, CTGF-expressing tumor cells are present in 
hypoxic regions of experimental tumors in vivo or in clinical samples and this 
has been attributed to the ability of CTGF to confer protection against hypoxia-
mediated apoptosis (Bennewith KL, et al. 2009). Taken together these 
evidences underline an important role of CTGF in pancreatic cancer onset and 
development. 
 
CTGF has been identified as a direct target gene of YAP-TEAD in mammals 
cell and several GGAATG motifs for TEAD-binding at the promoter region of 
CTGF gene have been reported (Zhao B. et al. 2008). CTGF mediates the 
growth-stimulating and oncogenic function of YAP-TEAD complex. Although 
CTGF is a known target of both TGFβ and the Hippo signaling pathway, the 
transcriptional mechanism that converges on CTGF expression involved in the 
crosstalk between these pathways has been described for the first time in 
malignant mesothelioma cells (Fujii M et al. 2012). Several studies have 
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reported the interactions between Smad and YAP/TAZ. Varelas et al. showed 
that YAP/TAZ controls the nuclear-cytoplasmic shuttling of Smad2/3–4 
complexes and regulates the nuclear accumulation of Smad complexes in 
mouse embryonic stem cell (Varelas X et al. 2008).Likewise Fujii et al. 
demonstrated a crosstalk between YAP and SMAD3 (Fujii et al. 2012) (Figure 
12). Since the weakness of this binding other components were hypothesized to 
take part of the complex and p300 was found, as well as TEAD (Wu S et al. 
2008; Zhang H et al. 2009). TGF-β is a powerful cytokine produced by many 
different cell types, with effects on multiple cell types. TGF-β can induce 
extremely variable responses, mainly through the Smad2/3-dependent pathway. 
For example, TGF-β induces growth arrest and apoptosis in epithelial cells and 
it can also activate fibroblasts. Subsequent studies further revealed that TGF-β 
acts as a tumor suppressor in premalignant cells as well as cells progressing 
through the early stages of carcinogenesis; furthermore, it exerts prooncogenic 
effects in metastatic tumors (Roberts AB and Wakefield LM 2003). Upon TGF-β 
stimulation, Smad2 and Smad3 form complexes with Smad4 and accumulate in 
the nucleus (Massagué J et al. 2005).p300, a transcriptional co-activator, binds 
with Smad3 and Smad2 and enhances Smad-induced transactivation of target 
genes (Nishihara A et al. 1998). Recruitment of p300 frequently plays a core 
role not only in enhancing transactivation but also in binding other proteins to 
stabilize protein complexes (Fujii M et al. 2006). As previously described, tumor 
cell–derived CTGF plays an important role in the proliferation of breast cancer 
cells (Zhao B et al. 2008) and growth of pancreatic tumors (Bennewith KL et al. 
2009). In addition CTGF also affects vascularization, migration, and epithelial-
mesenchymal transition in the context of oncogenic properties (Wahab NA and 
Mason RM 2006). In the transformed mesothelium, the activation of the Hippo 
pathway synergizes with the TGF-β pathway signaling to increase CTGF 
production and thereby amplify the profibrotic and colony-stimulating effects of 
TGF-β and potentially inducing other pro-tumorigenic effects in the 
microenvironment (Fujii et al 2012). In conclusion, determining the proper way 
to regulate CTGF expression, by directly target CTGF, is critical for clinical 
applications. The mechanism that allows CTGF to exert its effects has not yet 
been clarified. Further research regarding CTGF expression and its functions 
might lead to the discovery of new targets that could be used to regulate CTGF 
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expression. 
 
 
 
 
 
 
 
Figure 12. Schematic model of CTGF promoter activation through TGFb/Smad signaling 
and disturbance of the NF2/Hippo pathways. Because of the genetic disturbance in NF2 
and/or Lats2, Yap was dephosphorylated and constitutively translocated to the nucleus. On the 
other hand, upon TGFb stimulation, Smad2/3 and Smad4 associate, move to the nucleus, make 
a complex with YAP/TEAD, and recruit p300 to the promoter to activate CTGF expression _ 
Convergent signaling in the regulation of connective tissue growth factor in malignant 
mesothelioma. Fujii M et al. Cell Cycle 2012; 11(18):3373-9. 
 
 
 
 
 
 
 
 
4. THE BISINDOLYLMALEIDE I (GF 109203X) 
 
 
 
The bisindolylmaleimides, derivatives of staurosporine, are widely used as 
specific inhibitors of protein kinase C (PKC) isoforms (Figure 13). 
Bisindolylmaleimide I (GF 109203X) and IX (Ro 31-8220) are the most 
commonly used PKC inhibitors (Toullec D et al. 1991; Wilkinson SE 1993; Davis 
PD et al. 1989). GF 109203X is a competitive inhibitor with respect to ATP (Ki = 
14 ± 3 nM) and displayed high selectivity for PKCα compared to five different 
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protein kinases. Toullec et al. studied GF 109203X in two cellular models: 
human platelets and Swiss 3T3 fibroblasts (Toullec D et al. 1991). In these 
systems, the role of PKC in signal transduction has been extensively 
investigated (Rozengurt E 1986). GF 109203X resulted as efficient as 
staurosporine on PKC (IC50 = 10 nM) and was much less active against cAMP-
dependent protein kinase (IC50 = 2 µM) phosphorylase kinase (IC50 = 0.7 µM). 
GF 109203X was also inactive against 3 tyrosine kinases, namely EGF, 
platelet-derived growth factor, and insulin receptors (IC50 > 50 µM). Finally, GF 
109203X inhibited myosin light chain kinase in human platelets at higher 
concentrations than those required to suppress PKC activity in those cells. 
Beltman et al. (Beltman J et al. 1996) used five different bisinolylmaleides to 
evaluate targeted PKC isoforms. They found that Ro-31-8220 was selective 
inhibitor of calcium-, diterpine-, and phorbol ester-activable PKC isozymes α 
and ε, while GF 109203X was an equally effective inhibitor of basal PKC activity 
composed of α, ε and ξ of activated PKC. Based on several analyses, Beltman 
et al. concluded, that GF 109203X is less selective for particular PKC isozymes 
than Ro-31-8220, although the molecular reasons for these observations were 
not explained. A group from Leicester in 1996 compared staurosporine with its 
analogues (including GF 109203X) for the following properties: their effects on 
the cell cycle at equicytostatic concentrations, the time dependency and 
reversibility associated with their cytostatic properties, and their acute cytotoxic 
potential (Courage C et al. 1996). They reported that GF 109203X induces a 
potent G2/M arrest in synchronised cells, but by day 4 this phenomenon had 
been replaced by a weak G0/1 block. The primary cell cycle target of the 
staurosporine analogues is probably G2/M. If inhibition of PKC activity is 
important for their antiproliferation elicited, one might suppose that agents of 
similar high specificity for PKC would exert similar effects on the cell cycle. 
Conversely PKC did not appear to play an important role in these mechanisms. 
In fact results from this publication suggest that inhibition of PKC per se is not 
the primary arbiter of the growth arrest caused by these compounds. This 
interpretation is consistent with another investigation which demonstrated that 
inhibition of PKC activity could not be directly related to cell growth arrest 
induced by these compounds (Courage C et al. 1995). As PKC is not the prime 
determinant of the antiproliferative effect of these agents, among the major 
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targets, the prime candidates are the cyclin-dependent kinases (cdks), which, in 
concert with cyclins, are the essential components of the cell cycle machinery 
(Norbury C and Nurse P. 1992). Additional studies demonstrated that 
staurosporine blocks the progression of human lymphocytes through G0/1 
between the cyclin D and cyclin E restriction points and markedly suppresses 
phytohaemagglutinin-stimulated cyclin E expression (Gong J et al. 1994). It 
remains to be elucidated whether the bisindolylmaleimides affect cyclins and/or 
cdks. Finally, all five compounds have reported to inhibit cell growth more 
effectively after exposure for a longer time period and their cytostatic ability 
diminishes by drug removal after one day. These observations indicate that to 
achieve therapeutic efficacy dose, schedules might have to be chosen such that 
they yield significant drug levels over long periods of time. One advantage of 
cancer treatment with these modulators of signal transduction pathways might 
be the possibility that they exert cytostasis and not cytotoxicity, perhaps thus 
minimizing undue toxicity to the host.  
 
 
 
 
 
Figure 13. Structures of staurosporine and its four analogues.Differential effects of 
staurosporine analogues on cell cycle, growth and viability in A549 cells. Courage C et al. Br J 
Cancer 1996; 74(8):1199-205. 
 
 
 
 
4.1 GF 109203X effects on different pathways 
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Several additional pharmacological effects of bisindolylmaleimides have been 
reported. For example, Hers et al. reported that GSK-3, a key kinase in insulin-
induced activation of glycogen synthase, is potently and directly inhibited by GF 
109203X and Ro-31-8220 (Hers I et al. 1999). They reported that Ro-31-8220 is 
the more potent inhibitor of GSK-3 activity, with an approximately 100 times 
lower IC50 value than GF 109203X. While, GF 109203X has little effect on 
insulin-induced inhibition of GSK-3, under conditions where it would be 
expected to potently inhibit PKC activity (Toullec D et al. 1991). This strongly 
suggests that PKC, although it has previously been implicated in GSK-3 
regulation (Goode N et al. 1992), is not involved in this process.Another 
example that demonstrates the wide range of bisindolylmaleimides interactions 
is reported in 2008. The Wnt/β-catenin signaling pathway plays important roles 
in cell differentiation. Activation of this pathway has been shown to inhibit 
adipogenesis in cultured 3T3-L1 preadipocytes and mice. Cho et al. reported 
that GF 109203X inhibits adipogenesis by increasing the stability of β-catenin 
protein in 3T3-L1 preadipocyte cells. In particular it acts inhibiting adipocyte 
differentiation through activation of the Wnt/β-catenin signaling pathway (Cho M 
et al. 2008). Moreover GF 109203X increases β-catenin responsive 
transcription and up-regulates intracellular β-catenin levels in HEK293 cells and 
3T3-L1 preadipocytes. Finally, GF 109203X significantly decreased intracellular 
lipid accumulation and reduced expression of important adipocyte marker genes 
including peroxisome-proliferator-activated receptorγ (PPAR γ) and CAATT 
enhancer-binding protein α (C/EBPα) in 3T3-L1 preadipocytes. Alessi et al. 
have also shown that Ro 318220 and GF 109203X are not selective inhibitors of 
the mixed PKC isoforms (Alessi DR 1993). They demonstrated that both 
MAPKAP-Kl and p70 S6 kinase are inhibited with similar potency by Ro 318220 
and GF 109203X. This is due to the similarity in the amino acid sequence of the 
catalytic domain of p70 S6 kinase and the N-terminal kinase domain of 
MAPKAP-Kl to the catalytic domain of PKCα.  
 
First report concerning the modulation of multidrug resistance (MDR) proteins 
by bisindolylmaleimide derivatives were published by Gekeler et al (Gekeler V 
et al 1995). Using Human leukemia cell line HL60 and its non-P-gp MDR 
subline, they demonstrated that GF 109203X affected transport function is most 
	   45	  
likely associated with MRP/P-gp protein (the main representative of MDR 
proteins family). Furthermore, they observed that GF 109203X does not 
significantly alter the expression of the mrp/P-gp gene at the mRNA level. The 
authors supposed that, either a PKC dependent function could be disturbed by 
GF 109203X, i.e. phosphorylation of MRP/P-gp, or/and the compound interacts 
directly with the drug transporter. A year later the same group published results 
from similar studies performed on MDR-1/P-gp-transfected cells (Gekeler V et 
al. 1999) At up to 1µM final concentrations of GF 109203X, at which many PKC 
isozymes should be blocked substantially, no cytotoxic or MDR-reversing 
effects were seen. Thus, similarly to previous results, Gekeler et al. concluded 
that GF 109203X influences MDR mostly via direct binding to P-gp, but they did 
not confirm the concept of a major contribution of PKC to P-gp-associated 
MDR. The role of bisindolylmaleimide derivatives in multidrug resistance of 
cancer cells was investigated also by Budworth et al. (Budworth J et al. 1996). 
In contrast to previously observations, they found that neither GF 109203X nor 
Ro 31-8820 decreased efflux of the P-gp probe rhodamine 123 from MCF-7/Adr 
cells, where the most potent P-gp inhibitor was apparently staurosporine. It is 
possible that in MCF-7 breast cancer cells, P-gp activity depends on isozyme of 
PKC family, which is not inhibited by tested bisindolylmaleimide derivatives, but 
could be blocked by staurosporine. The possibility that bisindolylmaleimides-
mediates MDR modulation is cell-type specific is supported by results published 
by Merritt et al. regarding Ro 31-8820 (Merritt JE et al. 1999).   
 
 
Figure 14.  Schematic illustration of bisindolylmaleimides action on intracellular 
signaling.The pro- and antiapoptotic effects are indicated _ Bisindolylmaleimides in anti-cancer 
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therapy - more than PKC inhibitors. Pajak B et al. Adv Med Sci 2008; 53(1):21-31.  
 
 
EXPERIMENTAL PROCEDURES  
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Antibodies siRNAs and primers  
 
Anti-YAP (for ChIP), anti TEF-1, anti IgG, anti pan-Acetyl and pan-Phospho 
antibodieswere obtained from Santa Cruz Biotechnology. Anti-YAP (for western 
blotting) and Anti-phospho-YAP (S127) was obtained from Cell Signaling. Alexa 
Fluor 488-conjugated secondary antibodies were obtained from Invitrogen. 
SMARTpool ON-TARGETplus YAP1 siRNA and non-targeting siRNA were 
obtained from Thermo scientific. PKCα siRNA were obtained from Santa Cruz 
Biotechnology. TaqMan®probes for real time PCR analysis (mRNA expression) 
were obtained from Applied Biosystem, primers for real time PCR (for ChIP 
assay) were obtained from MWG/Operon, with the following sequences: 
 
Forward:  5’ TTGGTGCTGGAAATACTGCG 3’ 
 
Reverse:  5’ CTCAGCGGGGAAGAGTTGTT 3’ 
 
The kinase inhibitory library waspurchased from Enzo Life Sciences. 
 
GF 109203X HYDROCHLORIDE was obtained from Sigma-Aldrich and 
resuspended in dimethyl sulfoxide (DMSO). 
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Cell cultures and transfection methods 
 
Human pancreatic carcinoma cell lines (PK-9, MIA PaCa-2, PANC-1) were 
kindly provided by G. Feldmann (Cell, 2007) and propagated in DMEM high 
glucouse (LONZA) supplemented with 10% FCS (LONZA), 1X vitamin solution 
(Sigma), 1X non-essential amino-acid solution (NEAA, Biosource), 1X 
Sodiumpyruvate (Gibco) and 1X Penicillin-Streptomycin (LONZA). The 
intermediary cells formed during acinar-to-ductal metaplasia (HPNE) were 
cultured in DMEM high glucouse (LONZA) supplemented with M3 Base culture 
medium (Incell), 10% FCS, 25µg/ml Gentamycin (LONZA) and 10ng/ml EGF 
(R&D Systems). Human YAP siRNA sequences (On-TARGETplusTM SMART 
pool, Dharmacon RNA Technologies) and Non-targeting Pool (Dharmacon) 
were transfected with INTERFERinTM siRNA transfection reagent (Polyplus 
transfection, 50nM) following the manufacturer’s recommendations in PK-9 
cells. Cells were treated with GF 109203X (1µM) for 24 or 48 hours, adding the 
compound directly into cell culture medium.   
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Immunofluorescence staining and drug screening 
 
The experimental procedure used in the drug screening has been extensively 
optimized in pilot experiments before running the screening experiment. Cell 
density was the first parameter we tested because of the possible interference 
with YAP localization. Moreover, the cell confluence level is critical for 
discriminating the boundary of single cells by the software and thus making a 
correct analysis. Likewise, the incubation times and the concentrations of the 
primary and secondary antibodies are important to obtain an image of enough 
good quality to be used for quantitative purposes. At the end of pilot 
experiments, PK-9 cells were seeded on OptiPlate-96 Black, Black Opaque 96-
well Microplate (PerkinElmer) at a density of 5000 cells/well, to obtain a 70% 
confluence at the end of the assay. The library of known kinase inhibitors was 
resuspended in DMSO and diluted in PBS 1X. The compounds were 
administrated at the final concentration of 1µM, directly in the culture medium 
24 hours after the cell seeding and incubated for 24 hours. This temporal range 
allowed us to observe changes in YAP localization, without extensive citotoxic 
phenomena. Cells were fixed with 3.7% paraformaldehyde (PFA) for 15 minutes 
at room temperature. Cells were then treated for 10 minutes with 
permeabilization buffer (300 mM sucrose, 0.2% Triton X-100) and then for 15 
min with blocking buffer (2% Bovine Serum Albumin in PBS). Primary antibody 
against YAP (1:500) and secondary fluorophore conjugated (Alexa 488) 
antibody (1:10000) were diluted in PBS + BSA 0.2%. DAPI (1.5 µg/ml) in PBS + 
BSA 0.2% was used to detect nuclei. PerkinElmer image plate reader Operetta 
was used for imaging and evaluation. The ratio between Nuclear and 
Cytoplasmic signal represents the mean of single cells for every well and it were 
normalized to untreated control. The Z score was calculated to evaluate the 
significance of results from the screening. Z score was calculated as follow: Z = 
(X – µ) / σ.  X = normalized sample ratio, µ = mean, σ = standard deviation.  
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Western Blot analysis 
 
Whole cell extracts were obtained using Laemmli buffer, afterwards separated 
on 10% SDS-PAGE gels and transferred to PDVF membranes. Membranes 
were incubated with the following primary antibodies: anti-YAP (1:500), anti-
Phospho-YAP (Ser127) (1:500) (Cell Signalling) and anti-ACTIN (1:1000) 
(Santa Cruz Biotechnology). The corresponding peroxidase-labeled secondary 
antibody (Santa Cruz Biotechnology)was detected using ECL western blotting 
reagents (GE Healthcare). 
 
 
 
 
2 Dimensional Electrophoresis 
 
Proteins were extracted using a lysis buffer (8 M urea, 4% CHAPS, 50 mM 
dithioerythritol and 0,0002% Bromophenol blue) and rehydrated with 8 M urea, 
2% CHAPS, 20 mM dithioerythritol, 0.8% IPG buffer, carrier ampholytes pH 6-
11 linear. The first dimension isoelectric focusing (IEF) was performed 
inimmobiline dry strips (GE) with a pH range from 7 to 4. IEF was performed on 
IPGphor (GE) according to the manufacturer recommendations. The gels were 
then equilibrated in 6 M urea, 3% SDS, 375 mM Tris pH 8.6, 30% glycerol, 2% 
DTE and then incubated with 3% iodoacetamide (IAA) and traces of 
bromophenol blue (BBP). The second dimension was performed using an 8% 
SDS-PAGE gel. Transfer and detection were carried out as previously 
described. 
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Immunoprecipitation assay 
 
1mg of cellular extract from PK-9 cells was used as INPUT for each 
immunoprecipitation reaction.  40µl of protein G Agarose (equilibrated with 
RIPA buffer: 50mM TRIS HCl pH 7.5, 150mM NaCl, 1% NP-40, 0,5% 
Nadeoxycholate, 0,1% SDS, 1mM EDTA, 2% glycerol) were added with 10µg of 
antibody of interest (anti-YAP, anti-TEAD, anti-pan Phosho, anti-pan Ac, or anti-
IgG1), in batch for 2 hours at 4°C. Then every sample was loaded with 10µg of 
cellular extract, in batch 1 hour at 4°C. To remove nonspecific linking proteins 
three washes with RIPA buffer were performed. To elute antibody-antigen 
complexes for Western Blot analyses 40µl of 2x Leammli solution were added; 
samples were boiled 5min and microcentrifuged at 14000 rpm for 2 minutes. 
Samples were immediately immunoblotted to detect immunoprecipitated 
proteins. 
 
 
 
 
RT-qPCR analysis 
 
Primers to be used in RT-qPCR experiments after ChIP assay were designed 
with Primer3 software. The selected sequences were tested against public 
databases (NBLAST) to confirm the identity of the genes. For mRNA expression 
analysis, PK-9 cell cultures were collected and lysed by addition of RP1 buffer 
(Agilent total RNA isolation mini kit) and total RNA was isolated. 1µg of total 
RNA was reverse-transcribed in 20µl using RevertAidTM first strand cDNA 
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synthesis kit (Fermentas life sciences), according to manufacturer’s instructions. 
Real-time PCR were performed with TaqMan® gene expression assays. For 
ChIP assay, DNA was extracted by phenol/chloroform/isoamyl alcohol, ethanol 
precipitated and resuspended in water. Real-time PCR were performed with 
SYBR GREEN master mix. The reactions were carried out on a CFX96TM real-
time system (BIO-RAD). Data were analyzed by averaging technical triplicates. 
Experiments were run at least four times. In mRNA expression experiments, Ct 
values of every gene were normalized to the housekeeping GAPDH, while in 
ChIP assays, the normalization were calculated by the following formula: (X– 
IgG) / INPUT, where X is the Ct of the sequence of interest derived from the 
immunoprecipitated DNA bound to the protein of interest; IgG is the Ct of the 
same sequence derived from the DNA immunoprecipitated with an irrelevant 
antibody and INPUT is the Ct derived from the total DNA before 
immunoprecipitation. Experiments were run at least four times. 
 
 
 
 
Toxicity assay 
 
PK-9 cells were seeded as previously described and treated at 10 different 
concentrations. 48 hours after the treatment, the cells were incubated with Cell 
proliferation reagent WST-1 (Roche) according to the manufacturer 
recommendations. Absorbance-based viability was detected after 4 hours using 
Infinite® M200 (Tecan) at two time points: the day of compound adding and 48 
hours after the treatment. The data were analyzed with GraphPadPrism 5.0 
(GraphPad, San Diego, CA) software. The IC50 was determined by fitting the 
data point with the sigmoidal curve.  
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Cell proliferation assay 
 
Five thousand PK-9 cells were seeded per well of E-plates (Roche), in 
triplicates. The cell growth curves were automatically recorded on the 
xCELLigence System (Roche) in real time. The cell attachment was monitored 
every 15 minutes by a cell electronic system. The doubling times were 
calculated according with cell index. The cell index is an arbitrary unit for 
displaying impedence. siRNAs transfection or treatment with GF 109203X were 
performed by replacing cell medium, including untreated control to operate at 
the same working conditions. Since the sensitivity of the system used, an 
optimization phase was required before starting, in order to evaluate the optimal 
level of cell seeding. Differences in the number of passages of the same cell 
line could introduce variability to the cell index curves. 
 
 
 
 
Soft agar assay 
 
PK-9 cells were previously treated with GF 109203X (1µM) for 24 hours or 
transfected with siRNAs against YAP for 48 hours. One thousand of viable cells 
(treated, transfected and controls) were seeded per well in 96 multi well in 
quadruplicates. Soft-agar assay was performed using Cell 
BiolabsCytoSelectTM 96-well cell transformation assay (Soft Agar Colony 
Formation), according to the manufacturer recommendations. Ten days after 
cell seeding, cell counting was performed as follow: agar solubilization solution 
and lysis buffer were added to every well and after incubation with CyQuant 
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Working Solution, fluorescence was measured using a 485/520 nm filter set.  
 
 
 
 
Annexin V staining and flow cytometry 
 
PK-9 cells (transfected with siRNAs against YAP and control siRNA) were 
trypsinized and stained with PE Annexin V and analyzed by flow cytometry 
using the Annexin V Apoptosis Detection kit (BD Biosciences) following the 
manufacturer’s instructions. Data were collected and analyzed on a BD 
FACSCanto using FACSDiva software. 
 
 
Chromatin Immunoprecipitation assay 
 
Chromatin Immunoprecipitation (ChIP) assay was performed using untreated 
and GF 109203X treated PK-9 cells. The cross-linking was obtained with 1% 
formaldehyde. Cell pellets were wash with PBS 1X and subsequently 
resuspended in Lysis buffer and sonicated 10 sec x 3 times, 65% power 
(Branson 450 SLPe digital probe sonicator). Sonicated chromatin was 
incubated overnight in batch at 4°C in Dilution buffer with anti-IgG, anti-YAP 
and anti-TEF-1. 1% of total lysate was used for INPUT control. DNA was 
extracted by the Phenol/Chloroform/Isoamyl-alcohol, ethanol-precipitated, and 
resuspended in water. ChIP products were amplified using SYBR GREEN 
master mix and specific primers (see above).  
 
The crucial aspects to set a good ChIP protocol has been:  
- incubation with formaldehyde: more than 10 minutes could cause an irreversible 
cross-linking; 
- sonication: time, number of pulses and amplitude have to be tested before 
starting and can be different depending on cell type. Since sonication buffer 
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contains SDS, its precipitation (on ice) can increase the density of the samples, 
causing bubbles that can alter the quality of the sonication; 
- antibodies: we changed different kinds of YAP antibody before choosing the 
best one. This is particular hard when the protein is not directly bound to DNA 
but to a transcription factor (as YAP with TEAD). The concentration has also to 
be evaluated.  
RESULTS 
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1. CRUCIAL ROLE OF YAP IN PDAC  
 
 
1.1 YAP protein is expressed in multiple PDAC cell lines 
 
Increased YAP levels were detected in breast, colorectal, lung, and prostate 
cancer (Steinhardt AA, et al. 2008). Moreover, several recent observations point 
to a role of YAP in PDAC. In addition to the mutations in some Hippo pathway 
components (Jones S, et al. 2008), amplification of the 11q22 locus, where YAP 
is located, has also been reported in this form of cancer (Bashyam MD, et al. 
2005). To evaluate the presence of YAP in PDAC cell models, we performed 
western blotting analysis on total cell lysates from different PDAC cell lines 
(Figure 1.1). YAP was expressed in all of the cell lines analyzed and a high YAP 
expression was found in 3 out of 7 cell lines: PK-9, PANC-1, BxPC-3, 
suggesting a relevance of this protein in PDAC cellsin vitro.  
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Figure 1.1: YAP expression in different PDAC cell lines.Western blotting analysis on the 
total cell lysate (left), and relative densiometric analysis (right). Actin was used has 
housekeeping gene for normalization.  
 
 
 
 
 
 
 
 
1.2 YAP silencing reduces the anchorage-independent growth 
of PK-9 cells and leads to a delay in cell proliferation at the 
exponential phase of growth 	  
Since the highest level of YAP expression was observed in PK-9 cells, and 
since It has been previously showed that YAP is responsible of the tumorigenic 
potential of PK-9 cells when xenografted into nude mice (Dong J, et al. 2007), 
we used this cell line as reference for YAP dependent PDAC cell model. To 
explore the significance of YAP expression in PDAC cells in vitro, we performed 
transient YAP silencing in PK-9 cells through RNA interference. YAP protein 
level was reduced to 30% of the original level in YAP-silenced cells compared 
to controls, as shown by western blotting analysis (Figure 1.2a).  
 
 
 
 	  
Figure 1.2a: Transient silencing of YAP in PK-9 cell line. YAP expression in PK-9 cells 
transfected by a control siRNA or with a pool of siRNAs against YAP (left), and relative 
densiometric analysis (right). 
 
 
 
 
Subsequently, two important parameters have been examined: the anchorage-
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independent growth and the cell proliferation. The ability of YAP-silenced cells 
to grow in anchorage-independent conditions was studied using soft agar 
colony formation assay  (Figure 1.2b). We seeded 1000 cells per well in 
quadruplicates and PK-9 cells were previously transfected with siRNAs against 
YAP or control siRNA for 48 hours. Ten days after cell seeding the counting 
was performed according to the manufacturer recommendations (see materials 
and methods). The number of colonies was reduced by 20% in YAP-silenced 
cells compared to controls. These results open the way to further investigation 
about a putative role of YAP in controlling the cell genetic programing involved 
in the regulation of anchorage-independent growth in PDAC cell lines and are 
consistent with the role of YAP in modulating the tumorigenic potential of PK-9 
cells in vivo.  
 
 
 
Figure 1.2b: Colony formation assay of PK-9 cells in the absence of YAP. Cells were 
transfected with siRNAs against YAP, grown for 10 days and colonies counted. 
 
 
 
 
 
Next we measured YAP dependent cell proliferation by monitoring in real time 
through xCELLingence system (Figure 1.2c). In this system cell attachment is 
detected by microelectrode sensors and is directly correlated to cell 
proliferation.We chose this technology because of the peculiar role of YAP in 
changing its activation status upon cell confluency. At low density, YAP is 
predominantly localized in the nuclear compartment, while, YAP translocates to 
the cytoplasm at high density (Zhao B, et al. 2007). We performed siRNAs 
transfection 24 and 72 hours after the cell seeding. We reported a significant 
growth delay 48 hour after the first silencing (time point: 72 hours), indicating 
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that functional ablation of YAP led to an inhibition of cell proliferation at the 
exponential phase, and thus a role of YAP during this growth phase, in PK-9 
cell lines. This can be explained by the fact that YAP co-transcriptional activity 
and pro-proliferation effect are prevalent when cells are in the low confluent 
status. We also observed a relevant reduction in the number of silenced cells 
after the plateau phase was reached (time point: 140 hours). This could be 
addressed to a role of YAP in inhibiting apoptosis activation during confluency. 
However the role of YAP in regulating apoptosis is controversial. It was 
proposed that this co-transcriptional factor can show oncogenic or tumor 
suppressor behavior depending on the cellular context, and consequently the 
choice of its partners, that determine the final outcome (Bertini, E. et al. 2009). 
In order to investigate whether the reduction in the number of adherent cells 
was due to apoptotic phenomena we used flow cytometry assay (Figure 1.2d). 
We collected both untransfected and transfected PK-9 cells at the steady state 
growth and stained with Annexin V. Then the samples were analyzed by flow 
cytometry and the percentage of cells at all of the cell cycle phases was 
reported in graph.  We excluded the presence of apoptosis in YAP silenced 
cells. Nearly all the cells belonged to the viable compartment, while the rate of 
apoptotic cells is not significantly different in both untransfected and transfected 
cells. Interestingly, we observed an increased number of cells into the “Q1” 
compartment in YAP silenced cells compare to control (about 10%). These 
features were consistent with change in cell morphology. To test this 
hypothesis, we performed an immunofluorescence assay, by incubating fixed 
cells with antibody against YAP and with DAPI. An image plate reader was used 
to visualize and measure the size of control and silenced cells (Figure 1.2e). 
Changes in cell and nuclear dimension and shape suggested the onset of 
senescence upon YAP silencing. This hypothesis will be subject of future 
studies but, in support to our hypothesis, a recent paper (Xie Q, et al. 2013) 
showed that silencing of YAP induces premature senescence. Therefore, 
together with previous observation, our results demonstrated a YAP 
involvement in regulating cell proliferation and anchorage-independent growth, 
thus identifying YAP protein as a potential target for PDAC treatment.  
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Figure 1.2c: Proliferation of PK-9 cells after siRNAs inhibition of YAP expression. Five 
thousand cells were seeded per well of E-plate in triplicate and trasfected with siRNAs against 
YAP (red line/siYAP), control siRNA (green line/scramble) or without siRNA (blue line/mock), 
after 24 and 72 hours. Cell attachment was monitored every 15 minutes by a real-time cell 
electronic system. The cell index is an arbitrary unit for displaying impedence. In the upper part 
of the panel Cell growth curves are reported;the quantification of cell proliferation 72, 120 and 
140 hours after the cell seeding are reported in the lower part. 
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Figure 1.2d: Knockdown of YAP does not induce apoptosis at the steady state 
growth.PK-9 cells were transfected with control siRNA or siRNAs targeting YAP 24 and 72 
hours after the cell seeding. Cells were collected and stained with PE Annexin V and analyzed 
by FACS. The rates of all cell cycle phases were quantified and reported in graph. 	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Figure 1.2e: Increased cell size after YAP silencing in PK-9 cells. PK-9 cells were 
transfected with control siRNA (Scramble) or siRNAs targeting YAP (siYAP) 24 and 72 hours 
after the cell seeding. Fixed cells were incubated with with antibody against YAP and DAPI 
staining. Cellular and nuclear areas were measured through the PerkinElmer microplate image 
reader, Operetta and reported in graph.   
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2. IDENTIFICATION OF A KINASE INHIBITOR, GF 
109203X, ABLE TO INDUCE YAP NUCLEAR 
RETENTION BY AFFECTING YAP POST 
TRANSLATIONAL MODIFICATIONS 
 	  
2.1 Development of a high content assay for the identification 
of molecules that interfere with YAP subcellular localization 
 
YAP is an attractive therapeutic target, but no inhibitors of YAP activity are 
currently available as therapeutic options. The identification of molecular entities 
targeting the effects of YAP overexpression in PDAC could pave the way to the 
identification of novel therapeutics for this lethal malignancy. YAP cytoplasmic 
accumulation is accompanied by phosphorylation on S127 from the Hippo 
pathway component Lats1/2, and consequent protein inactivity and degradation 
by 14-3-3 (Hao Y, et al. 2008; Zhao, B. et al. 2007). On the other hand, nuclear 
localization is a prerequisite for its co-transcriptional activity on specific gene 
promoters (Zhao B, et al. 2007). However a second level of post-translational 
regulation, i.e. acetylations on K494 and K497, occurs on YAP and finely drives 
its activation independently of the nuclear localization of the protein (Hata S, et 
al. 2012). We exploited the nucleo-cytosplasmic properties of YAP to set up a 
high content assay that quantified the protein localization inside PK-9 cells by 
mean of immunocytochemistry. We administered a library of 80 characterized 
kinase inhibitors (purchased from Enzo Life Sciences) for 24 hours at the final 
concentration of 1 µM, with the aim to find a molecule able to regulate YAP 
localization. Fixed cells were incubated with antibody against YAP and DAPI 
staining. Intracellular localization of endogenous YAP protein was visualized 
through the PerkinElmer microplate image reader, Operetta (non confocal 
mode). The ratio between nuclear and cytoplasmic regions was calculated and 
normalized to untreated control. The Z-score of this value is reported in figure 
2.1a. Most of the molecules did not have an effect on YAP localization being the 
ratio of the intensity of nuclear/cytoplasm close to controls. Only two 
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compounds lead YAP accumulation into the nucleus: GF 109203X and Ro 31-
8220 (Figure 2.1b). GF 109203X, also called Bisindolylmaleimide I, is known as 
a cell-permeable and reversible protein kinase C (PKC) inhibitor. It acts as a 
competitive inhibitor for the ATP binding site of PKC and shows high selectivity 
for the PKC family members with specific affinity for PKCα-, β1-, β2-, γ-, δ-, and 
ε-isozymes. The Ki value is 14 ± 3 nM being most affine for the PKCα isoform. 
Moreover it can also directly target multiple other proteins (see introduction). 
Further immunofluorescence confirmation assays showed higher reproducibility 
of the nuclear retention effect for GF 109203X (Figure 2.1c) while Ro 31-8220 
gave more variable results. While YAP results spread within the two subcellular 
compartments in untreated cells at our experimental conditions, we can see a 
significant nuclear accumulation after GF 109203X treatment.  
Therefore, since the high structural homology of the two compounds we chose 
to use only GF 109203X for further experiments. In conclusion, we developed a 
high content assay to screen libraries of compounds and successively identified 
molecules able to interfere with the protein subcellular localization. Through this 
assay we identified a molecule that is able to retain YAP protein within the 
nuclear compartment.  
 
 
	  	  
 
Figure 2.1a: Screening assay development. A kinase inhibitor library was administrated to 
PK-9 cells using a high-throughput approach (1 µM, 24hours). The ratio between nuclear and 
cytoplasmic regions was calculated and normalized to untreated control. The Z-score was 
reported in graph. 
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Figure 2.1b: GF 109203X and Ro 31-8220. Molecular structure of the two identified 
compounds. 
 
 
 
 
 
 
Figure 2.1c: Validation of one significant hit, GF 109203X, by immunofluorescence 
images. PK-9 cells were treated with GF 109203X 1 µM for 24 hours and compared with 
untreated cells (NTC). Fixed cells were incubated with antibody against YAP (green) and DAPI 
staining (blue). Intracellular localization of endogenous YAP protein was visualized through the 
PerkinElmer microplate image reader, Operetta (non confocal mode).  
 
 
 
 
 
 
 
 
 
GF109203X  Ro 31-8220  
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2.2 GF 109203X enhances YAP phosphorylation and 
acetylation, without affecting phosphorylation at Serine 127 	  
As already stated, YAP nuclear localization is a necessary, but not sufficient, 
condition to allow its transcriptional activity. Therefore we thought that GF 
109203X-induced nuclear accumulation could not necessarily lead to YAP 
activation but could depend on the level of post-translational modifications 
occurring on YAP protein and eventually lead to YAP inhibition. We searched if 
GF 109203X caused an alteration of the phosphorylation and acetylation 
pattern of YAP in standard serum conditions. By two dimensional western 
blotting we observed that GF 109203X induced a higher number of migratory 
species at different pI than those observed during standard serum conditions 
(Figure 2.2a). The appearance of migratory bands towards lower pH is 
compatible with the onset of phosphorylations on free hydroxyl groups or 
acetylation and methylation of aminogroups. When we treated the cell lysate 
with calf intestinal alkaline phosphatase (CIAP) many bands, but not all, 
disappeared showing that GF 109203X induces a complex cellular answer 
comprising phosphorylation events. However, and consistently with YAP 
nuclear localization after the treatment, GF 109203X does not induce YAP 
phosphorylation on S127 and it has no effect on YAP Ser127-P localization. As 
internal positive control, we used cell lysates obtained from confluent cells in 
which the condition of S127 is phosphorylated (Zhao, B. et al. 2007). These 
results are in line with western blotting analysis on total cell lysates from treated 
and untreated PK-9 cells (Figure 2.2b). Immunoblotting with antibodies against 
total YAP or YAP Ser127-P showed that the level of both YAP proteins does not 
undergo any change after the treatment.  	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Figure 2.2a: 2D western blotting on whole cell lysates.Filters were blotted with antibodies 
against YAP and YAP Ser127-P. As negative control for phosphorylation the treated sample 
was incubated with calf intestinal alkaline phosphatase (CIAP). As positive control for 
phosphorylation at Ser127, cell lysate from high density cell culture was used. 	  	  	  
	  	  
Figure 2.2b: western blotting analysis on total cell lysates. YAP expression level in 
untreated (NTC) and GF 109203X-treated (1µM) PK-9 cells. Filters werehybridized with 
antibodies against total YAP and YAP Ser127-P.	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In order to confirm the results obtained in 2D experiments we 
immunoprecipitated YAP protein and blotted using antibodies against pan 
phosphorylation and pan acetylation residues (Figure 2.2c). In YAP 
immunoprecipitated samples we observed increase of both acetylations and 
phosphorylations on YAP protein. Therefore GF 109203X deeply changes the 
post-translational status of YAP favoring the appearance of phosphorylations, 
with the exception P-S127, and of acetylations. These results suggest that GF 
109203X mechanism of action could be Hippo pathway-independent. Moreover 
the increased level of YAP acetylation after the treatment can explain the GF 
109203X-induced YAP nuclear accumulation.Anexample of YAP regulation 
depending on its acetylation status within the nuclear compartment, has been 
already described (Hata S et al. 2012). We speculated that the putative Hippo 
pathway-independent regulation of YAP and changes in PTMs, in particular on 
acetylation, after GF 109203X treatment could be indications of a new 
mechanism for YAP regulation, not tightly dependent on its subcellular 
localization. 
 
 
 	  
Figure 2.2c: YAP immunoprecipitation on whole cell lysates.Total extracts were 
immunoprecipitated with antibody against YAP, pan phospho (pan-P) and pan acetylation (pan-
Ac). 	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3. GF 109203X TREATMENT RESULTS IN A 
DOWNREGULATION OF YAP TARGET GENE, CTGF, 
LEADING TO A CELL GROWTH DELAY AT THE 
EXPONENTIAL PHASE AND A REDUCED 
ANCHORAGE-INDEPENDENT GROWTH  
 
 
3.1 GF 109203X mimics YAP silencing effects on anchorage-
independent growth and cell proliferation at the exponential 
phase of growth 
 
We previously showed the phenotypic effects of YAP functional ablation on cell 
proliferation and anchorage-independent growth. In order to investigate whether 
the identified compound could induce similar consequences through its ability to 
affect YAP subcellular localization, we repeated the assays above in PK-9 cells 
after GF 109203X treatment. We evaluated the cells capability to grow in 
anchorage-independent conditions by seeding PK-9 cells in soft agar (Figure 
3.1a). The first set of experiments was performed treating cells with GF 
109203X 1µM only at the moment of cell seeding. The number of colonies, 
counted ten days later, although we observed a clear decrease, was not 
significantly changed in treated cells compare to untreated control. In order to 
potentiate the effect of the compound, we decided to pretreat PK-9 cells with 
the same conditions used in the screening, before starting the colony formation 
assay, and then seed the same number of viable cells as in the previous 
experiment with a second dose of the compound. Interestingly we observed a 
marked reduction in the number of colonies in treated cells compare to control, 
concluding that after GF 109203X treatment PK-9 cells are not clonogenic 
anymore. Thus we identified a compound able to induce YAP relocalization that 
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leads to the same effect then YAP silencing in cell capability to growth in 
anchorage-independent conditions. 
 
 
 
 
	  
Figure 3.1a: Colony formation assay of PK-9 cells after GF 109203X treatment.Cells were 
treated with GF 109203X at 1 µM after the seeding in soft agar medium. Cells were previously 
cultured in PL medium without the compound (left) or with GF 109203X at 1 µM for 24 hours 
(right). The number of colonies was counted after 10 days. 
 
 
 
 
Cell proliferation was observed in real time through xCELLingence system as 
previously described (Figure 3.1b). We treated PK-9 cells with GF 109203X 
1µM 24 and 72 hours after the cell seeding. In order to compare the curve trend 
with the growth of YAP silenced cells, we also performed siRNAs transfections 
at the same time points. As already reported for YAP silencing, GF 109203X 
treatment induced a growth delay at the exponential phase of growth, i.e. 24 
hours after the second treatment. Furthermore the presence of GF 109203X in 
YAP silenced cells did not lead to an additive effect of the treatment. Taken 
together these data shown that GF 109203X treatment mimics the effects 
observed in YAP silenced cells on PK-9 cell growth, suggesting that GF 
109203X action is YAP-dependent. Since we reported no change in YAP 
expression level after the treatment, GF 109203X mechanism of action seems 
to be more related with YAP activity. Moreover, these results confirmed the 
relevance of cell growth conditions, especially cell density, in YAP study. These 
effects, complies with a YAP-dependent anti cancer action of the identified 
compound, have encouraged us to further investigate the role of GF 109203X 
as a YAP inhibitor. 
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Figure 3.1b: Proliferation of PK-9 cells after GF 109203X treatment.Five thousand cells 
were seeded per well of E-plate in triplicate and treated with: siRNAs against YAP (red line), 
control siRNA (blue line), GF 109203X 1 µM (purple line), GF 109203X 1 µM plus siRNAs 
against YAP (green line) 24 and 72 hours after the ell seeding. Cell attachment was calculated 
as described previously. Cell index was quantified 96 hours after the cell seeding. In the lower 
part: the quantification of cell index 96 hours after the cell seeding (left) and a bright-field 
microscopy image of untreated (NTC) and treated (GF 109203X) PK-9 cells at 72 hours (right) 
are reported. 
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3.2 GF 109203X reduces CTGF expression level in PK-9 cell line 
 
The connective tissue growth factor (CTGF) has been identified as a direct 
target gene of YAP and the transcription factor TEAD. Functional ablation of 
CTGF has been demonstrated to block YAP-stimulated cell growth and 
significantly reduces YAP-induced colony formation in soft agar (Zhao B, et al. 
2008). In order to investigate if the phenotypic effects described after GF 
109203X treatment can be caused by an alteration in CTGF expression, we 
performed quantitative real time PCR on mRNA from untreated and treated PK-
9 cells (Figure 3.2). Despite an unchanged level of YAP expression, both at the 
protein (Figure 2.2b) and mRNA level, in GF 109203X treated cells, we 
observed a substantial decrease of CTGF expression compared to control. We 
also examined CTGF expression level in YAP silenced cells. The expected 
reduction of YAP mRNA level after YAP silencing was associated with a 
moderate downregulation of CTGF expression. These results demonstrated that 
GF 109203X treatment negative regulates CTGF expression and suggested 
that this effect is not dependent on YAP expression level, but again, on the 
modulation of YAP activity at the post-translational level. Moreover, CTGF 
downregulation is able to explain the decrease of cell proliferation and 
anchorage-independent growth reported after GF 109203X treatment. 
 
 
 
 
Figure 3.2: CTGF expression decreases after GF 109203X treatment in PK-9 cell line.Cells 
were treated with GF 109203X 1 µM for 24 hours. The level of CTGF and YAP mRNA was 
determined by Q-RT-PCR, using GAPDH as reference gene and normalized to 
untreated/untransfected control. Mean values and standard deviations were calculated from 
triplicates of three independent repeats.  
	   73	  
3.3 GF 109203X effect on CTGF expression is PKCα-
independent  
 
Since GF 109203X was defined as a PKCα inhibitor (Toullec D, et al. 1991), we 
studied the role of this protein kinase in our model. In particular, we explored 
whether CTGF regulation by GF 109203X was dependent on PKCα expression 
level. We performed PKCα silencing through RNA interference in PK-9 cell line 
and evaluated CTGF mRNA levels by quantitative real time PCR (Figure 3.3). 
We observed that functional ablation of PKCα is not associated with change in 
YAP expression level, while CTGF transcript resulted upregulated. This result 
indicates that PKCα is clearly implicated in the regulation of CTGF mRNA level, 
however since its functional ablations leading to opposite results than GF 
109203X administration on the expression level of CTGF, this molecule is 
triggering more complex pathways than simply inhibit PKCα. Due to the 
difficulties in identifying the GF 109203X target responsible of these effects we 
decided to better investigate the nuclear activity of YAP after GF 109203X 
treatment on the CTGF promoter. 
 
 
 
 
Figure 3.3: CTGF and YAP expression in PK-9 cells after GF 109203X treatment and YAP 
or PKCαsilencing.Cells were treated with GF 109203X 1 µM for 24 hours or transfected with 
siRNAs against YAP or PKCα for 48 hours. The level of CTGF and YAP mRNA was determined 
by Q-RT-PCR, using GAPDH as reference gene and normalized to untreated/untransfected 
control. Mean values and standard deviations were calculated from triplicates of three 
independent repeats.  	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4. GF 109203X DISPLACES YAP PROTEIN FROM 
CTGF PROMOTER 
 
 
 
TEAD is the major partner for functional activity of YAP (Vassilev A, et al. 2001). 
YAP/TEAD cooperate to activate the transcription of a number of genes by the 
physical and functional co-presence on their promoter regions and CTGF 
(connective tissue growth factor) is considered one of the main, although not 
exclusive, representative target. We therefore chose to investigate the co-
presence of YAP and TEAD at the promoter of CTGF by chromatin 
immunoprecipitation in the region containing the putative TEAD-binding sites 
(Figure 4a) identified by Zhang H and coworkers and important for CTGF 
promoter activity (Zhang H, et al. 2009). DNA from Chromatin 
immunoprecipitation was extract and analyzed by Real time PCR (Figure 4b). 
The TEAD1/3/4 transcription factors have been demonstrated to play a critical 
role in the expression of YAP-dependent genes, in particular data from (ChIP)-
on-chip experiments shown that YAP and TEAD1 co-occupy >80% of the 
promoters pulled down by either of them in MCF10A cells (Zhao B, et al. 2008). 
We explored the presence of three members of TEAD family, using antibodies 
against TEF-1 (TEAD1), TEF-3 (TEAD4) and TEF-4 (TEAD2). Interestingly, we 
obtained more reproducible data only from TEAD1 immunoprecipitated material, 
suggesting that in our model this member is the most involved in binding the 
investigated CTGF promoter region. As shown in figure 4, YAP and TEAD1 are 
associated on the CTGF promoter region during exponential growth phase 
(untreated sample, NTC), while GF 109203X can displace YAP protein from 
CTGF promoter. On the other hand, TEAD1 binding seemed to be not affected 
by treatment, and it can be considered an internal positive control. These data 
indicate that GF 109203X can break the interaction between YAP and TEAD at 
the chromatin level on the CTGF promoter, likely causing a decrease in the 
expression level of CTGF mRNA, but this effect does not necessarily inhibit 
TEAD binding to DNA. YAP displacement is consistent with the reported 
reduction of CTGF mRNA level during GF 109203X administration. Furthermore 
these results underlined that YAP functionality and activity, being this protein a 
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co-transcriptional activator,primary dependent on its capability to interact with its 
targets, i.e. multiple transcription factors, more than its simple localization. This 
could explain how a compound able to lead a nuclear accumulation of YAP, can 
be its inhibitor at the same time. 
 
 
	  	  	  
Figure4a: Map of CTGF promoter region. The position of the two primers used for ChIP 
analysis is indicated. The amplified sequence includes the previously identified TEAD 
responsive elements (TRE). TSS indicates the transcription start site.  	  	  	  	  
	  	  	  
Figure 4b: Chromatin immunoprecipitation of YAP and TEF-1 at CTGF promoter. ChIP 
was performed using antibodies against YAP, TEF-1 and IgG. After DNA extraction, Real time 
PCR amplification was performed. The results were analyzed using IgG as a negative control 
and compared to not immunoprecipitated sample (INPUT). 
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5. GF 109203X TOXICITY ON PK-9 AND HPNE 
CELLS 
 
 
5.1 GF 109203X exhibits IC50 value significantly higher on PK-9 
cells then on HPNE immortalized cell line	  
 
Since the relevance of the identified compound in regulating YAP as a potential 
drug target, we decided to investigate whether GF 109203X could induce 
toxicity in PDAC cells. We performed a cell viability assay by incubating cells 
with WST. Figure 5.1 shows the toxicity curves on PK-9 and HPNE cells 
exposed to increasing doses of GF 109203X for 48 hours. The hTERT-HPNE 
cell line was developed from human pancreatic duct by transduction with a 
retroviral expression vector (pBABEpuro) containing the hTERT gene. hTERT-
HPNE cells have properties of the intermediary cells formed during acinar-to-
ductal metaplasia, which included their undifferentiated phenotype (Lee KM, et 
al. Biochem Biophys Res Commun 2003; 301(4):1038-44). The comparison 
between cancer cells and immortalized cells gave us a preliminary indication 
about the selectivity of the compound in affecting only cancer cells. 
Gemcitabine is the only drug used in PDAC treatment at the moment. It has an 
IC50 value of about 60nM in our cell line (data not shown). As reported in table, 
IC50 value of GF 109203X in PK-9 cells is in the low micromolar range, which 
can be considered an index of low toxicity compared to gemcitabine. 
Interestingly, the administration of GF 109203X did not cause toxic effect in 
HPNE cells at tested concentrations, underling chemical features exploitable for 
drug development 
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Figure5.1: GF 109203X-induced cell toxicity. PK-9 and HPNE cells were treated with 
increasing dose of GF 109203X (from 0,1 to 33µM) for 48 hours.The cell viability assay was 
performed by incubating cells with WST for 4 hours. The absorbance ratio is the signal from 
treated cells normalized to the untreated control. The IC50 value was calculated by nonlinear 
regression, using Graphpad Prism software.  	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5.2 GF 109203X shows differential toxic effects on different 
PDAC cell lines 
 
In order to have an overview of GF 109203X effect on PDAC cell lines, we 
extend the cell viability assay to MIA PaCa-2 and PANC-1 cells, as previously 
described. We reported in graph the values of cell viability after 48 hours 
treatment with GF 109203X 10µM (Figure 5.2a). We observed toxicity only in 
PK-9 cells that have shown the highest YAP expression, suggesting that GF 
109203X mechanism of action could depend on the presence of YAP within 
cells. However this hypothesis has to be further explored, taking into account 
the genetic backgroundof the analyzed cell lines. Table 5.2b summarizes the 
most common mutated genes in PDAC and their state in PK-9 MIA PaCa-2 and 
PANC-1 cells, as reported in literature (Kobari M, et al. 1986; Deer EL, et al. 
2010). The behavior of these cell lines is currently on study in our laboratory, in 
order to elucidate the cell specific response to GF 109203X treatment. 
 
 
 
Figure 5.2a: Cell viability assay on different PDAC cell lines. The analyzed cell lines 
express YAP at differential levels: high (PK-9), low (MIA PaCa-2) and intermediate (PANC-
1).Cells were treated with GF 109203X (10µM) for 48 hours and subsequently incubated with 
WST for 4 hours.  	  	  	  
	  
 
Figure 5.2b: PDAC cell lines genotype. Summary ofthe mutations present in analyzed cell 
lines of the most representative genes in PDAC, and schematic representation of YAP 
expression.  
PDAC cell lines KRAS CDKN2A TP53 SMAD4 YAP exp 
PK-9 G12D HD exons 1-3 R213X HD exons1-11 ++++ 
MIA PACA-2 G12D HD 248W WT + 
PANC-1 G12D HD 273H WT ++ 
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DISCUSSION	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This study allowed the identification of an inhibitor of YAP functionality, a small 
molecule called GF 10923X, an already known kinase inhibitor preferentially 
targeting PKCα. We characterized its molecular mechanism leading to YAP 
inhibition and this molecule, endowed with a brand new property, can now be 
thought as a potential lead to be used in diseases where YAP deregulation is 
observed, as may be pancreatic ductal adenocarcinoma. Here we reported lines 
of evidence demonstrating a new role of this compound in regulating YAP 
protein localization, thereby arresting YAP oncogenic activity in PDAC, in vitro. 
We developed a high throughput approach by which we identified this 
compound able to reduce YAP-induced proliferation and clonogenicity, despite 
it leads to increased YAP nuclear levels. The main inhibitory pathway of YAP 
protein is the Hippo pathway, that phosphorylates YAP at Serine127, causing its 
cytoplasmic accumulation and degradation (Zhao B et al. 2007). Together with 
the “classical” regulators, novel mechanisms have been recently reported. A 
novel cycle of YAP acetylation within the nucleus has been demonstrated 
following MMS-induced DNA damage (Hata S et al. 2012).GF 109203X-induced 
YAP nuclear accumulation is in line with the increased protein acetylation we 
observed after the treatment, further underlining the importance of post 
translational modifications (PTMs) in YAP localization and regulation. On the 
other hand we deviate from the simplistic association between YAP localization 
and its functionality, suggesting that its PTMs are crucial for the binding to its 
targets and thus for its regulation.  
The best characterized genetic lesions in evolving pancreatic adenocarcinoma 
include mutations of K-RAS, TP53, CDKN2A, SMAD4 and BRCA2. Our model, 
PK-9 cell line, shows a peculiar genotype: point mutations in K-RAS (G12D) 
and P53 (R213X) genes and homozygous deletions at SMAD4 and CDKN2A. In 
particular K-RAS plays an important role in pancreatic cancer etiology and 
development (Sugio K, et al. 1997; Luttges J, et al. 1999);the p53 tumor 
suppressor gene is inactivated in 40% to 75% of pancreatic cancers (Pellegata 
NS, et al. 1994) and cooperates with K-RAS in tumorigenesis (Kalthoff H, et al. 
1993). Likewise, DPC4 inactivation is always accompanied by inactivation of 
p16 (Cowgill SM and Muscarella P 2003), as observed in PK-9 cells. While loss 
of SMAD4/DPC4 interferes with the intracellular signaling cascades 
downstream from TGF-β and activin, resulting in decreased growth inhibition via 
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loss of proapoptotic signaling or inappropriate G1/S transition(Massague, J et 
al. 2000). In addition to these driving forces, the relevance of YAP in pancreatic 
cancer was suggested by J. Guo and colleagues, and confirmed in a recent 
publication by C. H. Diep (Guo J et al. 2006; Diep CH et al. 2012) in which they 
reported that YAP expression level results increased in PDAC in comparison to 
levels observed in chronic pancreatitis samples or in normal pancreatic tissues. 
Moreover YAP overexpression leads to immediate organomegaly followed by 
tumor formation in mouse model(Dong J, et al. 2007). Two distinct patterns of 
YAP distribution in tumor cells have been observed —with or without nuclear 
accumulation— implying different mechanisms by which Hippo signaling may 
be deregulated in cancer cells. Based on the mechanism of Yki/YAP 
inactivation by Hippo signaling, authors suggest that the former pattern could 
result from inactivation of tumor suppressors upstream of YAP, mutation of the 
S127 phosphorylation site, or perturbation of the nuclear-cytoplasmic shuttling 
machinery, whereas the latter pattern could be caused by YAP overabundance, 
either via gene amplification, increased transcription, or protein stabilization. In 
line with these findings,we reported YAP expression in all of the analyzed 
PDAC cell lines and YAP overexpression in 3 out of 7 cell lines. The stable 
presence of YAP is consistent with an important role of this protein in PDAC. 
Confirming this data, we observed that the functional ablation of YAP leads to 
an inhibition of cell proliferation and cell growth in anchorage-independent 
conditions at the exponential phase of growth in PK-9 cells. The controversial 
view of YAP as oncogene or tumor suppressor is underlined by its dual role in 
inhibiting apoptosis and promoting cell proliferation, and on the other hand in 
increasing the ability of p73 in inducing apoptosis (Blandino G et al. 2009). In 
our experimental conditions, we excluded the onset of apoptosis in YAP 
silenced cells after the confluence stage was reached. These data confirm cell 
density as a crucial parameter in YAP functionality and underline that reduction 
in cell proliferation is not necessary related with apoptosis.Additionally, the 
change in cellular shape and size suggested the induction of senescence, in 
line with the new finding that identified YAP as a regulator of this mechanism, 
through transcriptionally upregulating CDK6 expression (Xie Q et al. 2013). We 
are currently investigating this hypothesis in our model. The phenotypic effects 
we described in YAP silenced cells were observed also after GF 109203X 
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treatment and are tightly dependent on cellular confluence level. We reported a 
delay in cell proliferation and an inhibition of anchorage-independent growth 
only at the exponential phase of growth and at a cell density starting from fifty 
percent. The maintaining of these conditions, especially for screening 
development, has been crucial for evaluating the effects not dependent on 
changes in cell density.  
The potential interaction with a number of genes that displays deregulated 
expression in PDAC point to an important role of YAP in modulating aberrant 
signaling pathways that contribute to the pathogenesis of this disease (Guo J et 
al. 2006). YAP is located within a network of multiple pathways acting upstream 
and downstream our protein. For example, YAP has been reported to bind to 
p53 binding protein-2 (p53BP-2), an important regulator of the apoptotic activity 
of p53(Strano S et al. 2001). In addition, other transcription factors could 
potentially be co-activated by YAP, including: AP2, C/EBPα, c-Jun, Krox-20, 
Krox-24, MEF2B, NF-E2, Oct-4 and p73 (see introduction).Finally, YAP can 
also interact with the transforming growth factor-beta (TGF-β)/Smad signaling 
pathway(Ferrigno O et al. 2002),mediating the nuclear accumulation of SMADs 
in response to TGF-β responsiveness to cell density(Varelas et al. 2008 and 
2010). The capability of YAP to regulate a wide range of factors that are 
important in PDAC onset and development, makes it a critical factor in 
pancreatic cancer etiology. TEAD is the most potent YAP target, able to 
mediated YAP-induced cell growth and EMT in mammals. The connective 
tissue growth factor (CTGF) is a direct target gene of YAP and TEAD, playing 
an important role in growth-promoting function of YAP and its activity level is 
commonly used to evaluate YAP functionality (Zhao B et al. 2008). We reported 
that GF 109203X displaces YAP from the CTGF promoter region comprising the 
previously identified TEAD/YAP response elements (Zhang H et al. 2009), 
leading to a downregulation of CTGF expression. GF 109203X is a kinase 
inhibitor with specific affinity for PKC family members. In an attempt to identify 
the molecular target of GF 1093203X responsible of its effects on YAP 
functionality we silenced PKCα and evaluated CTGF expression level. The 
transient silencing of PKCα does not lead to a downregulation of CTGF 
expression, but preliminary data from real time PCR analysis shows that the 
silencing of PKCα correlates with an increase of CTGF expression, without 
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affecting YAP level. These results shows an involvement of PKCα in the 
modulation of CTGF expression level however they do not suggest that PKCα  
is the primary target of GF 109203X in the modulation of CTGF. The presence 
of a functional relationship between PKCα and YAP protein is still an open 
question. Future perspectives could be planned for further investigating the 
target of GF 109203X. For example an affinity chromatography linking GF 
109203X to a resin could be useful for identifying the kinase able to bind our 
compound. The subsequent silencing of the target or of the putative targets in 
our cell model could be used in order to explore its role in affecting YAP PTMs 
and/or binding to the promoter regions. Since we have not observed any 
alterations in YAP phosphorylation at Serine127 in GF 109203X treated cells, 
we discarded the hypothesis of a regulation mediated by the Hippo pathway. 
Chromatin immunoprecipitation experiments allowed us to demonstrate that the 
identified compound interferes with YAP binding to CTGF promoter, without 
affecting the presence of TEAD at the same region. In summary, in the model 
proposed GF 109203X acts most likely affecting differential signaling pathways 
than the Hippo pathway to modulate YAP functionality. However it causes an 
alteration in YAP PTMs, in particular phosphorylation and acetylation, the latter 
leads to its nuclear retention. In this mechanism, the YAP activity is not 
correlated with its nuclear localization, but with its capacity to participate in the 
transcriptional complex formation at promoter regions. GF 109203X treatment 
prevents the binding of YAP to the CTGF promoter, thereby inhibiting CTGF 
expression. Biological effects of CTGF include stimulation of proliferation, 
angiogenesis, migration, ECM production, cell attachment, cell survival and in 
some cell types apoptosis (Perbal B et al. 2001). Moreover different studies 
have shown that CCN genes are involved in tumorigenesis, and that CTGF is 
overexpressed in pancreatic cancers (Wenger C et al. 1999) and melanomas 
(Kubo M et al. 1998), so understanding mechanisms of CCN gene inhibition 
may be useful in new strategies for cancer therapy. In this study we reported 
that the GF 109203X-mediated downregulation of CTGF, through YAP binding 
inhibition, leads to a delay in cell proliferation and a reduced anchorage-
independent growth of pancreatic cancer cells at the exponential phase. Among 
the further investigations needed, a chemical optimization of the identified 
compound would be desirable in order to increase the potency of the compound 
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in decreasing CTGF expression levels. This would be important also to evaluate 
if the differential toxicity that we observed in between pancreatic cancer cells 
and immortalized HPNE cell lines is dependent on the inhibition of YAP 
functionality or rely alternative or nonspecific mechanisms. Taken all together, 
these data make GF 109203X a potential lead compound to be used in the drug 
development for YAP deregulated PDAC treatment.  
 
 
In conclusion, in my PhD project we identified for the first time to our knowledge 
a compound able to displace the co-transcription factor YAP from the promoter 
region of the CTGF gene, an important YAP target gene, leading to an inhibition 
of cell proliferation and of the capability of PK-9 cells to grow in anchorage-
independent conditions.   
 
 
 
 
NOTES 
 
In our laboratory, another PhD student is focused on testing the effect of GF 
109203X and of three more chemical analogues on different PDAC cell lines. 
Her results regarding YAP nuclear retention, CTGF expression and cell toxicity 
are described, together with the data presented in this thesis, in an article 
recently submitted.  
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OTHER PROJECTS 
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In addition to my thesis project, I collaborated with other members of my 
laboratory in projects regarding the role of the RNA binding protein, HuR, in 
breast cancer cell lines. Article number one has been submitted (in attach), 
article number two is currently in preparation. The second article will be 
reported as attachment in the final thesis. Here I describe my specific 
contribution to both projects. 
 
 
Article 1: Loss of PKCδ/HuR interaction is necessary to 
doxorubicin resistance in breast cancer cell lines  
 
Elisa Latorre* #, Ilaria Castiglioni*, Pamela Gatto°, Stephana Carelli# 
Alessandro Quattrone+, Alessandro Provenzani* 
 
* Laboratory of Genomic Screening, Centre for Integrative Biology, University of Trento, Trento, 
Italy 
+ Laboratory of Translational Genomics, Centre for Integrative Biology, University of Trento, Italy 
# Pharmacology Laboratory, Health Sciences Dept, University of Milan, Italy 
° High Throughput Screening Facility, Centre for Integrative Biology, University of Trento, Italy 	  
 
Here we demonstrated that the genotoxic stimulus induced by doxorubicin 
triggers PKCδ interaction with HuR and leads to HuR phosphorylation on serine 
221 and 318 and cytoplasmic translocation. This series of events is crucial to 
elicit the death pathway triggered by doxorubicin and is also necessary to 
promote HuR function in post-transcriptional regulation of gene expression, 
since genetic ablation of PKCδ brought to HuR inability to bind its target 
mRNAs. PKCδ and HuR proteins were coordinately downregulated together 
with the HuR-regulated TOP2A mRNA, a doxorubicin target, in in vitro selected 
doxorubicin resistant human breast cancer cell lines upregulating the multidrug 
resistance marker ABCG2. Therefore, we show here that PKCδ, HuR and 
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TOP2A constitute a network mediating doxorubicin efficacy in breast cancer 
cells.  
I participated evaluating the differential expression of the proteins of interest 
between wild type and doxorubicin resistant breast cancer cell lines, specifically 
I evaluated HuR, ABCG2, PKCδ, TOP2A proteins. Western blotting analysis 
was performed with a SDS-PAGE Electrophoresis System (Biorad) in two 
populations of doxorubicin-resistant breast cancer cells we previously 
developed (Latorre et al. 2012), MCF-7/doxoR and MDA-MD231/doxoR. I 
observed a downregulation of PKCδ in doxoR populations with respect to the 
parental doxorubicin-sensitive cells, as was HuR, while it did not occur in the 
SK-BR3/no-doxoR population used as negative control. Interestingly, TOP2A 
protein level decreased significantly in breast cancer resistant cells that showed 
low HuR expression level consistently with what we observed in the stably HuR 
silenced MCF-7 cells. Moreover, the ABCG2 transporter, a marker for the 
doxorubicin resistance phenotype, was found to be overexpressed, compared 
to parental cells, in the MCF-7/doxoR and in the MDA-MD231/doxoR but not in 
the SK-BR3/no-doxoR strain.  	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Article 2: HuR and MALAT1: a new ribonucleic complex 
regulating cancer staminality in human breast tumor 
 
 
Elisa Latorre PhD§#, Stephana Carelli*#, Ilaria Castiglioni*§, Vito 
D’Agostino PhD§, Giacomina Moro MD°, Andrea Luciani MD PhD#, 
Giorgio Ghilardi MD#,  Annamaria Di Giulio PhD#, Alfredo Gorio 
PhD# and Alessandro Provenzani PhD§ 
 
§ University of Trento, Center for Integrative Biology, Genome screening laboratory - Trento 
(ITALY) 
# University of Milan, Department of Health Sciences, Laboratory of Pharmacology - Milan 
(ITALY) 
° San Paolo Hospital - Milan (ITALY) 
(*)These	  authors	  contributed	  equally	  to this work 
 
 
In the second project, we showed a new gene expression regulatory 
mechanism in which the lincRNA, MALAT1, cooperates with the RNA binding 
protein, HuR, and the histone de-acetylase, HDAC6, into a new 
ribonucleoprotein complex playing an important role in gene expression of 
cancer stem cells (CSCs) markers. In order to identify where and if HuR was 
bound to MALAT1 and to the chromatin, I screened different chromatin regions 
in the lincRNA regulated genes by chromatin immunoprecipitation assay (ChIP) 
looking for regions where HuR was bound. I identified, within the CD133 locus, 
a strong HuR binding signal, we called D-region. HDAC6 is a well known de-
acetylase that possesses histone deacetylase activity and represses 
transcription in particular of CD133 gene (Pellacani et al. 2011 Mol. Cancer 10; 
94-108). I also confirmed that in our cellular model both HuR and HDAC6 are 
present on the CD133 D-region (Figure 1). Finally I performed a ChIP 
experiment in the presence or absence of RNase, concluding that the HuR 
binding to the chromatin is dependent on the presence of RNA (figure 2). 
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Figure 1. Ribonucleoprotein complex HuR-HDAC6 binds to Prominin (CD133) gene 
intronic regulatory region in mammospheres. A. Map of prominin 1 locus organization. Black 
and white boxes indicate exons. The small black bars named from A to D are the regions 
previously investigated by ChIP. The RNA hairpin is representative of MALAT1 lincRNA and the 
small black bar named E is the regions investigated by RIP for the binding of HuR and HDAC6. 
B. ChIP analysis on the Prominin1 locus in mammospheres. The results are reported as 
semiquantitative PCR on samples derived from immuneprecipitation with anti-HuR or anti-
HDAC6 antibodies. Input is the positive control, IgG is the negative one. The different primer 
pairs are named with letters (A-D) matching the map in panel A. A strong positive signal is 
reported on the D region for both anti-HuR or anti-HDAC6 antibodies. 
 
 
 
 
 
Fugure 2. RNA depended ChIP analysis on the D region of Prominin1 locus. The results 
are reported as semiquantitative PCR on samples derived from the immuneprecipitation with 
anti-HuR, anti-HDAC6 or anti-ENX antibodies in presence or absence of RNAase A 
pretreatment (with + and without -). Input is the PCR positive control, IgG and H3 are 
respectively the negative and the positive ChIP controls. H2O is the control without DNA. The 
white harrow indicates the self annealing primers band, the black one points to the PCR positive 
signal band. 
 
 
 
 
We therefore analyzed in details the proliferative and adhesive capability of 
mammospheres in the absence of HuR in vivo and in vitro. I demonstrated that 
in the absence of anchorage HuR KD mammosphers showed impaired growth, 
as they formed less colonies if cultured in soft agar (Figure 3a) and I observed 
less proliferative behavior of HuR KD mammospheres after 8 passages (Figure 
3b).  
	   
A 
B 
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Figure 3.HuR knocked down mammospheres cellular characterization.A. Colony formation 
in anchorage independent conditions. Scramble (scrm) and HuR KD mammospheres were 
seeded in soft agar. The graph on the left shows the quantification of the relative fluorescent 
units (RFU). Pictures on the right show the colonies ten days after the cell seeding. B.Cell 
growth curves of scrambled (scrm) and HuR silenced (HuR KD) mammospheres, reported as 
total cell number counted at each culture passage (p1-p8). Pictures on the right show 
scrambled and HuR KD mammospheres from p2 culture passage in direct light. Scale bar 
correspond to 100um. 
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